Non-ionic block PVP PLA block copolymers and pharmaceutical compositions derived therefrom

ABSTRACT

There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145° C., n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the block copolymers have a number average molecular weight (M n ) of at least 3000 Da. Polymers demonstrating flexibility in formulating multiple low-solubility active pharmaceutical ingredients (APIs) are described. Liquid and dry pharmaceutical formulations comprising an API are described, along with delivery methods, uses, and kits. APIs may include, e.g. flurbiprofen, celecoxib, acetaminophen, or propofol. Also provided is a method of synthesizing the PVP-PLA block copolymers by (i) initiating polymerization of D,L-Lactide from the initiator alcohol x to form poly(lactic acid), adding a xanthate to form a PLA macroinitiator, and polymerizing NVP onto the PLA macroinitiator, by controlled polymerization, to form the block copolymer compound of Formula (I).

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority of U.S. ProvisionalPatent Application No. 62/479,582 entitled NON-IONIC BLOCK COPOLYMERSAND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM filed on Mar. 31,2017, and from U.K. Application No 1705287.9 entitled NON-IONIC BLOCKCOPOLYMERS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM filed onMar. 31, 2017, both of which are hereby incorporated by reference.

FIELD

The present disclosure relates generally related to carriers for activepharmaceutical ingredients (APIs). More particularly, the presentdisclosure relates to block copolymers for micellar delivery of APIs.

BACKGROUND

PVP-PLA is a non-ionic block copolymer of polyvinylpyrrolidone (PVP) andpoly(D,L lactide) (PLA). PVP-PLA technology may be used for theformulation of active pharmaceutical ingredients (APIs) for delivery toindividuals in need thereof, and is particularly useful for delivery ofAPIs of low solubility in water, or APIs that are water-insoluble. Thetechnology has the ability to form micelles independently of the pH whenthe polymer concentration in water is above the critical micellarconcentration (CMC) and to entrap APIs within their cores in theprocess. Such micelles are disrupted when the polymer concentrationdecreases below the CMC. Following this principle, API-loaded PVP-PLAmicelles will begin to release their API content upon dilution, e.g.,after injection into blood; however the CMC of the PVP-PLA/APIformulation may vary depending on the nature of the drug so entrapped.

Although PVP-PLA is valuable for drug delivery, the technology remainschallenging, for example due to one or more of: inefficient non-costeffective methods of synthesis; limitations on the ability to loaddifferent APIs; or limitations to the amount of API that may be loaded.

Therefore, there remains a need for PVP-PLA block copolymers that can bemanufactured efficiently. There remains a need for flexible PVP-PLA drugdelivery technologies with the ability to load respective APIs insufficiently high concentration and/or to load a range of APIs. Thereremains a need for PVP-PLA block copolymer species having capacity toload API's in sufficiently high concentration so as make theadministration of the PVP-PLA+API formulation as infrequent as possible.

SUMMARY

It is an object of the present disclosure to obviate or mitigate atleast one disadvantage of previous approaches.

In a first aspect, the present disclosure provides PVP-PLA blockcopolymers as defined in Formula I:

wherein x is an initiator alcohol having a boiling point greater than145° C., n is, on average, from 20 and 40, and m is, on average, from 10and 40, wherein the block coplymers have a number average molecularweight (M_(n)) of at least 3000 Da.

In another aspect, there is provided a nanovehicle delivery systemcomprising micelles formed of the PVP-PLA block copolymers.

In another aspect, there is provided a dry pharmaceutical compositioncomprising the PVP-PLA block copolymers in molecular association with atleast one active pharmaceutical ingredient (API).

In another aspect, there is provided a liquid pharmaceutical compositioncomprising nanoparticles formed of the PVP-PLA block copolymers andcomprising at least one active pharmaceutical ingredient (API).

In another aspect, there is provided a method of delivering at least oneactive pharmaceutical ingredient (API) to a subject in need thereof,comprising administering the dry pharmaceutical composition to thesubject.

In another aspect, there is provided a method of delivering at least oneactive pharmaceutical ingredient (API) to a subject in need thereof,comprising administering the liquid pharmaceutical composition to thesubject.

In another aspect, there is provided the dry pharmaceutical compositionor the liquid pharmaceutical composition for use in delivery of at leastone active pharmaceutical ingredient (API) to a subject.

In another aspect, there is provided a kit comprising the drypharmaceutical composition or the liquid pharmaceutical composition, andinstructions for use in delivery of at least one active pharmaceuticalingredient (API) to a subject.

In one aspect, the above-described block copolymers may find applicationin mitigation of haemolytic effects.

In one aspect, the above-described block copolymers may find applicationin mitigation of haemolytic activity of a cargo molecule.

In another aspect, there is provided a method of preparing PVP-PLA blockcopolymers as defined in Formula I:

wherein x is an initiator alcohol having a boiling point greater than145° C., n is, on average, from 20 and 40, m is, on average, from 10 and40, and the block copolymers have a number average molecular weight (Mn)of at least 3000 Da the method comprising: initiating polymerization ofD,L-Lactide from the initiator alcohol x to form poly(lactic acid)(PLA), adding a xanthate to the PLA to form a PLA macroinitiator, andpolymerizing NVP, by controlled polymerization, onto the PLAmacroinitiator to form the block copolymer compound of Formula I.

Other aspects and features of the present disclosure will becomeapparent to those ordinarily skilled in the art upon review of thefollowing description of specific embodiments in conjunction with theaccompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present disclosure will now be described, by way ofexample only, with reference to the attached Figures.

FIG. 1 depicts micelle size distribution obtained from three differentbatches of PVP-PLA polymer.

FIG. 2 depicts the XRPD patterns for flurbiprofen (top line) and itsphysical mixture with PVP-PLA (bottom line).

FIG. 3 depicts the XRPD pattern of lyophilized flurbiprofen cake thatcontains similar amount of the API as physical mixture shown in FIG. 2.

FIG. 4 shows pictures, with panel A showing the picture of thefreeze-dried cake and the solution obtained after reconstitution of thecake with water for injection at flurbiprofen concentration of 50 mg/mL,and panel B showing a closer view of the solution of panel A.

FIG. 5 depicts the particle size distribution of a flurbiprofenformulation reconstituted at 50 mg/mL.

FIG. 6 depicts XRPD pattern of the FLU product at time zero and afterT=3 months of storage in both conditions.

FIG. 7 depicts particle size distributions of flurbiprofen formulationsprepared using WB-4 and WB-7 polymers.

FIG. 8 depicts XRPD patterns for acetaminophen API and lyophilized cakeof the drug product.

FIG. 9 depicts a picture of the freeze-dried acetaminophen cake and thesolution obtained after reconstitution of the cake with water forinjection at the acetaminophen concentration of 50 mg/mL.

FIG. 10 depicts particle size distribution for APAP formulationreconstituted at 50 mg/mL.

FIG. 11 depicts particle size distributions for acetaminophenformulations prepared using two different polymers WB-4 and WB-7 andreconstituted at 50 mg/mL.

FIG. 12 depicts a picture of the freeze-dried celecoxib cake and thesolution obtained after reconstitution of the cake with water forinjection at the CEL concentration of 25 mg/mL.

FIG. 13 depicts particle size distribution for celecoxib formulationreconstituted at 25 mg/mL.

FIG. 14 depicts a photograph of formulations of PPF prepared with WB-4to WB-8 polymer samples before filtration and freeze-drying.

FIG. 15 depicts volume-average size distribution of particles informulations of PPF and polymers WB-4 to WB-8 before filtration andfreeze-drying.

FIG. 16 shows that particle size distribution for PPF formulationsprepared using polymers WB-4, WB-5, and WB-6 is monomodal and that thevolume-average size of micelles varies from ca. 15 to 150 nm.

FIG. 17 depicts time concentration profiles of FLU fin rats following anIV dose of 2.5 (lower line), 10 (middle line) or 30 mg/kg (upper line)PPI-1501.

FIG. 18 depicts a comparative plasma time-concentration profiles of FLUfollowing the IV dosing of a 2.5 mg/kg FLU solution (redrawn fromReference 1; bottom line) and following IV dosing of PPI-1501 at 2.5mg/kg (top line).

FIG. 19 depicts two compartmental model fitting of the plasmaconcentration profile of FLU dosed as PPI 1501 at the IV dose of 2.5mg/kg.

FIG. 20 depicts two compartmental model fitting of the plasmaconcentration profile of FLU dosed as PPI 1501 at the IV dose of 10mg/kg.

FIG. 21 depicts two compartmental model fitting of the plasmaconcentration profile of FLU dosed as PPI 1501 at the IV dose of 30mg/kg.

FIG. 22 depicts two compartmental model fitting of the plasmaconcentration of FLU dosed as a simple solution at the IV dose of 2.5mg/kg.

FIG. 23 depicts comparative simulation of human FLU concentrationfollowing a single IV dose of 100 mg FLU in solution vs PPI 1501formulation and FA. The horizontal line corresponding to 4 mg/Lconcentration represents the threshold pain re-occurrence level.

FIG. 24 comparative simulation of human FLU concentration following bidIV dose of 100 mg FLU in solution vs PPI 1501 formulation and FA. Thehorizontal line corresponding to 4 mg/L concentration represents thethreshold pain re-occurrence level.

FIG. 25 Comparative simulation of human FLU concentration following q6 hIV dose of 50 mg FLU in solution vs PPI 1501 formulation and FA. Theblue horizontal line corresponding to 4 mg/L concentration representsthe threshold pain re-occurrence level.

FIG. 26 shows percent haemolysis measured for non-formulatedflurbiprofen and its formulation both at the same concentration of 5mg/mL.

FIG. 27 shows percent haemolysis for different concentrations of drug informulations of flurbiprofen, celecoxib and acetaminophen.

DETAILED DESCRIPTION

PVP-PLA Block Copolymers

In one aspect, there are provided PVP-PLA block copolymers as defined inFormula I:

wherein: x is an initiator alcohol having a boiling point greater than145° C., n is, on average, from 20 and 40, and m is, on average, from 10and 40, wherein the block copolymers have a number average molecularweight (M_(n)) of at least 3000 Da.

By “initiator alcohol” is meant a species having a hydroxyl groupcapable of serving a substrate for polymerization, in this case ofpoly(D,L lactide) (PLA). It will be understood that reference to an“initiator alcohol” in the context of the above structure is intended tomean the reacted form thereof.

All boiling points referred to herein are at standard pressure. Theboiling point of the initiator alcohol may be selected achieve desiredefficiency of polymerization without problematic evaporation of theinitiator alcohol.

In one embodiment, the initiator alcohol has a boiling point of greaterthan 150° C. In one embodiment, the initiator alcohol has a boilingpoint of greater than 160° C. In one embodiment, the initiator alcoholhas a boiling point of greater than 170° C. In one embodiment, theinitiator alcohol has a boiling point of greater than 180° C. In oneembodiment, the initiator alcohol has a boiling point of greater than190° C. In one embodiment, the initiator alcohol has a boiling point ofgreater than 200° C.

In one embodiment, the initiator alcohol is selected from the groupconsisting of: 1-hexanol; 1-heptanol; diethylene glycol monoethyl ether;diethylene glycol mono methyl ether; triethylene glycol mono methylether; tetraethylene glycol mono methyl ether; oligo-ethylene glycolmono methyl ethers of formula II

wherein a≥5;

oligo-ethylene glycol mono ethyl ethers of formula III

wherein b≥1;

and mixtures thereof.

In one embodiment, x is diethylene glycol mono ethyl ether (DEGMEE).

The “number average molecular weight” (M_(n)) will be understood as theordinary arithmetic mean or average of the molecular masses of theindividual macromolecules. It is determined by measuring the molecularmass of n polymer molecules, summing the masses, and dividing by n:

${\overset{\_}{M}}_{n} = \frac{\sum_{i}{N_{i}M_{i}}}{\sum_{i}N_{i}}$

Number average molecular weight of a polymer can be determined, e.g., bygel permeation chromatography, viscometry e.g. via the Mark-Houwinkequation, colligative methods such as vapor pressure osmometry,end-group determination or proton NMR.

In one embodiment, the block copolymers are capable of formingnanoparticles with at least one active pharmaceutical ingredient (API),wherein the nanoparticles are suitable for administration to a subject.Nanoparticle formation may solubilize the API.

By “nanoparticles” are meant particles having a size of less than 200nm. In some instances, the nanoparticles may be less than 100 nm insize. Nanoparticles may be sized to avoid or reduce renal excretion. Forexample, nanoparticles may be size greater than 15 nm. The nanoparticlesreferred to herein may be micelles.

By “micelle” will be understood as a supramolecular self-assemblycomprised of molecules that arrange themselves in a generally sphericalform in aqueous solutions. The formation of a micelle is a response tothe amphipathic nature the PVP-PLA block copolymers, which contain bothhydrophilic regions (PLA groups) as well as hydrophobic regions (PVPgroups). A typical micelle in aqueous solution forms with thehydrophilic regions of the polymer in contact with surrounding solvent,sequestering the hydrophobic regions in the micelle centre. Herein, theterm “micelle” or “micellar” also may be used to refer to the structureof a dried form of a previously liquid colloidal composition of micellarnanoparticles, wherein some elements of a micellar structure areretained in dried form, or wherein the dried form readily reformsmicelles upon hydration.

Molecules, including APIs, can be solubilized through formation of ananoparticles comprising the molecule or API. The nanoparticles may be ananodispersion.

By “nanodispersion” is meant a dispersion of nanoparticles in a medium.

By “suitable for administration to a subject” is meant that thenanoparticles or a suspension of nanoparticles possesses properties thatrender them suitable for delivery to a subject, e.g. to meet safetyrequirements. The suspension of nanoparticles may, for example, meetrequirements set out in USP 788, which inter alia sets limitations onthe amount of particulate matter permitted in material intended forparenteral administration. These requirements are considered to be metif the number of particulates per (injection) container is less than6000 for particles of 10 microns or greater, and less than 600 forparticles equal of 25 microns or greater.

In some embodiments, the suspension of nanoparticles may be essentiallyclear. In some embodiments, the suspension may be free of visibleparticulate. By “essentially clear” is generally meant free of visibleparticulate matter. In some embodiments, the suspension may be free ofsub-visible particulate.

In some embodiments, the suspension of nanoparticles may have an opticaltransmittance indicative of the general clearness of a solution. Theoptical transmittance may, for example, be an OD₆₅₀ of greater than 70%,80%, 90%, 95%, 96%, 97%, or 98%, depending on requirements.

In some embodiment, wherein the block copolymers have a M_(n) of lessthan 12,000 Da, 11,000 Da, 10,000 Da, 9,000 Da, 8000 Da, 7000 Da, or6000 Da. In some embodiment, wherein the block copolymers have a M_(n)of less than 7000 Da. In some embodiment, wherein the block copolymershave a M_(n) of greater than 4000 Da, 5000 Da, or 6000 Da.

Group 1

In one embodiment, the block copolymers are capable of formingnanoparticles with at least one active pharmaceutical ingredient.

By “capable of forming nanoparticles” is meant that the block copolymersspontaneously form nanoparticles comprising the block copolymers and theAPI when mixed under suitable conditions. The nanoparticles may bestable, meaning that they persist as nanoparticles (subject toequilibrium) in an aqueous solution for a particular period of time. Forinstance, the nanoparticles may be stable for at least one day. Thenanoparticles may be stable for at least two days. The nanoparticles maybe stable for at least three days. Stability may be indicated by lack offormation of undesirable visible particulate or sediment. Nanoparticlesformation may solubilize the API.

In one embodiment, the block copolymers are capable of formingnanoparticles with at least flurbiprofen (FLU). In one embodiment, n is,on average, from 20 to 28. In one embodiment, n is, on average, 21 to27. In one embodiment, m is, on average, from 11 to 37. In oneembodiment, m is, on average, from 12 to 36. In one embodiment, thePVP-PLA block copolymers have a number average molecular weight of 3000Da to 6600 Da. In one embodiment, the PVP-PLA block copolymers have anumber average molecular weight of 3100 Da to 6500 Da. In oneembodiment, the PVP-PLA block copolymers have a number average molecularweight for the PLA block of 1400 Da to 2900 Da. In one embodiment, thePVP-PLA block copolymers have a number average molecular weight for thePLA block of 1500 Da to 2800 Da.

When a characteristic of the “PLA block” is referred to herein, it willbe understood that this refers to the poly(lactic acid) component of thepolymers. This value can be obtained, e.g., by using the values of Mncalculated by proton NMR in Table 20 for PLA-PEOX and subtracting themolecule weight of PEOX (121.2) and that of the initiator alcohol used(134.2).

In one embodiment, the PVP-PLA block copolymers have a number averagemolecular weight for the PVP block of 1200 Da to 4200 Da. In oneembodiment, the PVP-PLA block copolymers have a number average molecularweight for the PVP block of 1300 Da to 4100 Da.

When a characteristic of the “PVP block” is referred to, it will beunderstood that this refers to the polyvinylpyrrolidone component of thepolymers. This value can be obtained, e.g., by using the values of Mncalculated by proton NMR in Table 20 for PVP.

In one embodiment, the PVP-PLA block copolymers have a ratio of thenumber average molecular weight of the PLA block to the number averagemolecular weight of the PVP block (PLA:PVP) of about 0.3 to about 1.4.In one embodiment, the PVP-PLA block copolymers have a ratio of thenumber average molecular weight of the PLA block to the number averagemolecular weight of the PVP block (PLA:PVP) of about 0.4 to about 1.3.

In some embodiments, the PVP-PLA block copolymers may be defined by someor all of the parameters set forth for Group 1 polymers in Table 20. Insome embodiments, the PVP-PLA block copolymers may possess some or allof the characteristics of polymers WB-DMAP, WB-1, WB-2, WB-3, WB-4,WB-5, WB-6, WB-7, or WB-8 from Table 20.

Group 2

In one embodiment, the PVP-PLA block copolymers are capable of formingnanoparticles with at least two different active pharmaceuticalingredients (APIs).

By “capable of forming nanoparticles with at least two different APIs”will be understood that the block copolymer can at least formnanoparticles with the at least two different APIs independently. Insome embodiments, the nanoparticles may form nanoparticles with amixture of the at least two different APIs.

In one embodiment, the at least two different APIs comprise flurbiprofenand celecoxib. In one embodiment, n is, on average, from 21.5 to 28. Inone embodiment, n is, on average, from 22 to 27. In some embodiments, nmay be, on average, about 24. In one embodiment, m is, on average, from18 to 37. In one embodiment, m is, on average, from 19 to 36. In someembodiments, m may be, on average, about 29. In one embodiment, thePVP-PLA block copolymers have a number average molecular weight of 4600Da to 6600 Da. In one embodiment, the PVP-PLA block copolymers have anumber average molecular weight of 4700 Da to 6500 Da. In someembodiments, a number average molecular weight may be about 5700 Da. Inone embodiment, the PVP-PLA block copolymers have a number averagemolecular weight for the PLA block of 1600 Da to 2900 Da. In oneembodiment, the PVP-PLA block copolymers have a number average molecularweight for the PLA block of 1700 Da to 2800 Da. In one embodiment, thePVP-PLA block copolymers have a number average molecular weight for thePVP block of 1900 Da to 4200 Da. In one embodiment, the PVP-PLA blockcopolymers have a number average molecular weight for the PVP block of2000 Da to 4100 Da. In one embodiment, the PVP-PLA block copolymers havea ratio of the number average molecular weight of the PLA block to thenumber average molecular weight of the PVP block (PLA:PVP) of 0.3 to1.4. In one embodiment, the PVP-PLA block copolymers have a ratio of thenumber average molecular weight of the PLA block to the number averagemolecular weight of the PVP block (PLA:PVP) of 0.4 to 1.3. In oneembodiment, the PVP-PLA block copolymers have a weight average molecularweight (M_(w)) of PLA in the block copolymers of 35% to 60%, based onthe total weight of the polymer. In one embodiment, the PVP-PLA blockcopolymers have a weight average molecular weight (M_(w)) of PVP in theblock copolymers of 40% to 65%, based on the total weight of thepolymer. In some embodiments, the average M_(w) of PLA is about 45% andthe average M_(w) of PVP is about 55%.

“Weight average molecular weight” (M_(w)) will be understood as anotherway of describing the molar mass of a polymer, wherein larger moleculeshave a larger contribution than a smaller molecule. The mass averagemolar mass is calculated by:

${\overset{\_}{M}}_{w} = \frac{\sum_{i}{N_{i}M_{i}}}{\sum_{i}{N_{i}M_{i}}}$

wherein Ni is the number of molecules of molecular mass Mi. Mass averagemolecular mass can be determined, e.g., by static light scattering,small angle neutron scattering, X-ray scattering, and sedimentationvelocity, relative gel permeation chromatography (GPC), or sizeexclusion chromatography (SEC).

In some embodiments, the PVP-PLA block copolymers may be defined by someor all of the parameters set forth for Group 2 polymers in Table 20. Insome embodiments, the PVP-PLA block copolymers may possess some or allof the characteristics of polymers WB-1, WB-2, WB-3, WB-4, WB-5, WB-6,or WB-8 from Table 20.

Group 3

In one embodiment, the block copolymers are capable of formingnanoparticles with at least three different active pharmaceuticalingredients (APIs).

By “capable of forming nanoparticles with at least three different APIs”will be understood that the block copolymer can at least formnanoparticles with the at least three different APIs independently. Insome embodiments, the nanoparticles may form nanoparticles with amixture of the at least three different APIs.

In one embodiment, the at least three different APIs comprise at leastthree of flurbiprofen, celecoxib, acetaminophen, and propofol. In oneembodiment, the at least three different APIs comprise all four offlurbiprofen, celecoxib, acetaminophen, and propofol. In one embodiment,n is, on average, from 21.5 to 28. In one embodiment, n is, on average,from 22 to 27. In some embodiments, n may be, on average, about 24. Inone embodiment, m is, on average, from 25 to 37. In one embodiment, mis, on average, from 26 to 36. In some embodiments, m may be, onaverage, about 31. In one embodiment, the PVP-PLA block copolymers havea number average molecular weight of 4800 Da to 6600 Da. In oneembodiment, the PVP-PLA block copolymers have a number average molecularweight of 4900 Da to 6500 Da. In some embodiments, the number averagemolecular weight is about 5900 Da. In one embodiment, the PVP-PLA blockcopolymers have a number average molecular weight for the PLA block of1600 Da to 2900 Da. In one embodiment, the PVP-PLA block copolymers havea number average molecular weight for the PLA block of 1700 Da to 2800Da. In one embodiment, the PVP-PLA block copolymers have a numberaverage molecular weight for the PVP block of 2700 Da to 4200 Da. In oneembodiment, the PVP-PLA block copolymers have a number average molecularweight for the PVP block of 2800 Da to 4100 Da. In one embodiment, thePVP-PLA block copolymers have a ratio of the number average molecularweight of the PLA block to the number average molecular weight of thePVP block (PLA:PVP) of 0.3 to 1.0. In one embodiment, the PVP-PLA blockcopolymers have a ratio of the number average molecular weight of thePLA block to the number average molecular weight of the PVP block(PLA:PVP) of 0.4 to 0.9. In one embodiment, the PVP-PLA block copolymershave a weight average molecular weight (M_(w)) of PLA in the blockcopolymers of 35% to 60%, based on the total weight of the polymer. Inone embodiment, the PVP-PLA block copolymers have a weight averagemolecular weight (M_(w)) of PVP in the block copolymers of 40% to 65%,based on the total weight of the polymer. In some embodiments, theaverage M_(w) of PLA is about 45% and the average M_(w) of PVP is about55%.

In some embodiments, the PVP-PLA block copolymers may be defined by someor all of the parameters set forth for Group 3 polymers in Table 20. Insome embodiments, the PVP-PLA block copolymers may possess some or allof the characteristics of polymers WB-1, WB-2, WB-3, WB-4, WB-5, orWB-6.

Group 4

In one embodiment, the block copolymers may be a subset of those capableof forming nanoparticles with at least three different activepharmaceutical ingredients (APIs).

In one embodiment, n is, on average, from 24 to 28. In one embodiment, nis, on average, from 25 to 27. In some embodiments, n may be, onaverage, about 26. In one embodiment, m is, on average, from 25 to 33.In one embodiment, m is, on average, from 26 to 32. In some embodiments,m may be, on average, about 29. In one embodiment, the PVP-PLA blockcopolymers have a number average molecular weight of 5400 Da to 6600 Da.In one embodiment, the PVP-PLA block copolymers have a number averagemolecular weight of 5500 Da to 6500 Da. In some embodiments, the numberaverage molecular weight is about 6000 Da. In one embodiment, thePVP-PLA block copolymers have a number average molecular weight for thePLA block of 2200 Da to 2900 Da. In one embodiment, the PVP-PLA blockcopolymers have a number average molecular weight for the PLA block of2300 Da to 2800 Da. In one embodiment, the PVP-PLA block copolymers havea number average molecular weight for the PVP block of 2700 Da to 3700Da. In one embodiment, the PVP-PLA block copolymers have a numberaverage molecular weight for the PVP block of 2800 Da to 3600 Da. In oneembodiment, the ratio of the number average molecular weight of the PLAblock to the number average molecular weight of the PVP block (PLA:PVP)of 0.5 to 1.0. In one embodiment, the ratio of the number averagemolecular weight of the PLA block to the number average molecular weightof the PVP block (PLA:PVP) of 0.6 to 0.9. In one embodiment, the weightaverage molecular weight (M_(w)) of PLA in the block copolymers is 35%to 50%, based on the total weight of the polymer. In one embodiment, theweight average molecular weight (M_(w)) of PVP in the block copolymersis 50% to 65%, based on the total weight of the polymer. In someembodiments, the average M_(w) of PLA is about 45% and the average M_(w)of PVP is about 55%.

In some embodiments, the PVP-PLA block copolymers may be defined by someor all of the parameters set forth for Group 4 polymers in Table 20.

Groups 1 to 4

In the above embodiments under Groups 1 to 4 and earlier, the numberaverage molecular weight may be as measured by proton nuclear magneticresonance (NMR).

In the above embodiments under Groups 1 to 4 and earlier, the weightaverage molecular weight may be is as measured by thermogravimetricanalysis (TGA).

In one embodiment, the PVP-PLA block copolymers have a polydispersityindex (PDI) of ≤1.8. In one embodiment, the PVP-PLA block copolymershave a polydispersity index (PDI) of ≤1.6. In one embodiment, thePVP-PLA block copolymers have a polydispersity index (PDI) of ≤1.5. Inone embodiment, the polydispersity index is ≤1.4. In one embodiment, thepolydispersity index is ≤1.3. In one embodiment, the polydispersityindex is ≤1.2. In one embodiment, the polydispersity index is ≤1.1. Inone embodiment, the PDI is as measured by gel permeation chromatographywith light scattering (GPC-LS).

Nanovehicle Delivery System

In one aspect, there is provided a nanovehicle delivery systemcomprising micelles formed of the above-described PVP-PLA blockcopolymers. By “nanovehicle delivery system” is meant nanoparticlesformed of the above-described block co-polymers. The nanoparticles mayconsist of the above-describe block co-polymers in some embodiments. Thenanovehicle delivery system may be useful for solubilizing anothermolecule, which may be of low solubility or hydrophobic. The nanovehicledelivery system may be useful for solubilizing one or more API, asdescribed herein.

Dry Pharmaceutical Formulation

In one aspect, there is provided a dry pharmaceutical compositioncomprising the above-described PVP-PLA block copolymers in molecularassociation with at least one active pharmaceutical ingredient (API).

By “dry pharmaceutical composition” is meant a formulation prepared bydrying (e.g., removing solvent) a mixture of the API and the blockcopolymers to form an intimate mixture of the API and the blockcopolymers. “Dry” here will be understood to mean “substantially dry”,and indicates that the at least about 90%, at least about 95%, 96%, 97%,98%, 99%, or 99.9%, of the solvent has been removed during the dryingprocess. The dry pharmaceutical composition may be in the form of a cakeof a powder. The term “powder” refers to a substantially dry,free-flowing, particulate material having high bulk density. Spray-driedpowders typically have a bulk density in the range of about 0.05-1.00g/cc, more typically between about 0.2-0.5 g/cc. Advantageously, powdersare suitable for incorporation into various non-intravenous dosageforms, including but not limited to, tablets, including rapiddisintegrating tablets, caplets, capsules, sachets, solutions,suspensions, creams, gels, ointments, pessaries, suppositories, enema,drops, aerosol or dry powder inhalers, and the like. The term “cake”, ascompared to a powder, refers to a non-flowing, non-particulate materialhaving a low bulk density, typically in the range of about 0.0001-0.05g/cc. In accordance with the methods disclosed herein, a cake may beformed, for example, as a result of lyophilization or freeze-drying.

By “molecular association” is meant that at least a portion of the APIis in intimate contact with the hydrophobic segment of the PVP-PLA blockcopolymers.

The solid pharmaceutical compositions may be in the form of, orformulated as, various dosage forms, in some embodiments. Examplesinclude, but are not limited to tablets, caplets, capsules, sachetformulations, films, lozenges, chewing gum, pastes, ointments, sprays,aerosol inhalers, dry powder inhalers, suppositories, pessaries, etc.

By “active pharmaceutical ingredient (API)” refers to an agent that hasa therapeutic or health-promoting effect when administered to a human oran animal, for example, an agent capable of treating or preventing adisease or condition. Examples of therapeutic agents include, but arenot limited to, drugs, prodrugs, vitamins and supplements.

APIs contemplated herein include, for example, individual compounds oflow solubility as defined herein include those drugs categorized as“slightly soluble”, “very slightly soluble”, “practically insoluble” and“insoluble” in USP 24, pp. 2254-2298; and those drugs categorized asrequiring 100 ml or more of water to dissolve 1 g of the drug, as listedin USP 24, pp. 2299-2304.

Exemplary compounds, include, without limitation; compounds from thefollowing classes: abortifacients, ACE inhibitors, α- and β-adrenergicagonists, α- and β-adrenergic blockers, adrenocortical suppressants,adrenocorticotropic hormones, alcohol deterrents, aldose reductaseinhibitors, aldosterone antagonists, anabolics, analgesics (includingnarcotic and non-narcotic analgesics), anesthetics, androgens,angiotensin II receptor antagonists, anorexics, antacids,anthelminthics, antiacne agents, antiallergics, antialopecia agents,antiamebics, antiandrogens, antianginal agents, antiarrhythmics,antiarteriosclerotics, antiarthritic/antirheumatic agents,antiasthmatics, antibacterials, antibacterial adjuncts,anticholinergics, anticoagulants, anticonvulsants, antidepressants,antidiabetics, antidiarrheal agents, antidiuretics, antidotes to poison,antidyskinetics, antieczematics, antiemetics, antiestrogens,antifibrotics, antiflatulents, antifungals, antiglaucoma agents,antigonadotropins, antigout agents, antihistaminics, antihyperactives,antihyperlipoproteinemics, antihyperphosphatemics, antihypertensives,antihyperthyroid agents, antihypotensives, antihypothyroid agents,anti-inflammatories, antimalarials, antimanics, antimethemoglobinemics,antimigraine agents, antimuscarinics, antimycobacterials, antineoplasticagents and adjuncts, antineutropenics, antiosteoporotics, antipagetics,antiparkinsonian agents, antipheochromocytoma agents, antipneumocystisagents, antiprostatic hypertrophy agents, antiprotozoals, antipruritics,antipsoriatics, antipsychotics, antipyretics, antirickettsials,antiseborrheics, antiseptics/disinfectants, antispasmodics,antisyphylitics, antithrombocythemics, antithrombotics, antitussives,antiulceratives, antiurolithics, antivenins, antiviral agents,anxiolytics, aromatase inhibitors, astringents, benzodiazepineantagonists, bone resorption inhibitors, bradycardic agents, bradykininantagonists, bronchodilators, calcium channel blockers, calciumregulators, carbonic anhydrase inhibitors, cardiotonics, CCKantagonists, chelating agents, cholelitholytic agents, choleretics,cholinergics, cholinesterase inhibitors, cholinesterase reactivators,CNS stimulants, contraceptives, debriding agents, decongestants,depigmentors, dermatitis herpetiformis suppressants, digestive aids,diuretics, dopamine receptor agonists, dopamine receptor antagonists,ectoparasiticides, emetics, enkephalinase inhibitors, enzymes, enzymecofactors, estrogens, expectorants, fibrinogen receptor antagonists,fluoride supplements, gastric and pancreatic secretion stimulants,gastric cytoprotectants, gastric proton pump inhibitors, gastricsecretion inhibitors, gastroprokinetics, glucocorticoids, α-glucosidaseinhibitors, gonad-stimulating principles, growth hormone inhibitors,growth hormone releasing factors, growth stimulants, hematinics,hematopoietics, hemolytics, hemostatics, heparin antagonists, hepaticenzyme inducers, hepatoprotectants, histamine H2 receptor antagonists,HIV protease inhibitors, HMG CoA reductase inhibitors, immunomodulators,immunosuppressants, insulin sensitizers, ion exchange resins,keratolytics, lactation stimulating hormones, laxatives/cathartics,leukotriene antagonists, LH-RH agonists, lipotropics, 5-lipoxygenaseinhibitors, lupus erythematosus suppressants, matrix metalloproteinaseinhibitors, mineralocorticoids, miotics, monoamine oxidase inhibitors,mucolytics, muscle relaxants, mydriatics, narcotic antagonists,neuroprotectives, nootropics, ovarian hormones, oxytocics, pepsininhibitors, pigmentation agents, plasma volume expanders, potassiumchannel activators/openers, progestogens, prolactin inhibitors,prostaglandins, protease inhibitors, radio-pharmaceuticals, 5α-reductaseinhibitors, respiratory stimulants, reverse transcriptase inhibitors,sedatives/hypnotics, serenics, serotonin noradrenaline reuptakeinhibitors, serotonin receptor agonists, serotonin receptor antagonists,serotonin uptake inhibitors, somatostatin analogs, thrombolytics,thromboxane A2 receptor antagonists, thyroid hormones, thyrotropichormones, tocolytics, topoisomerase I and II inhibitors, uricosurics,vasomodulators including vasodilators and vasoconstrictors,vasoprotectants, xanthine oxidase inhibitors, and combinations thereof.

Examples of APIs include, without limitation, acetaminophen,acetohexamide, acetylsalicylic acid, alclofenac, allopurinol, atropine,benzthiazide, carprofen, celecoxib, chlordiazepoxide, chlorpromazine,clonidine, codeine, codeine phosphate, codeine sulfate, deracoxib,diacerein, diclofenac, diltiazem, estradiol, etodolac, etoposide,etoricoxib, fenbufen, fendofenac, fenprofen, fentiazac, flurbiprofen,griseofulvin, haloperidol, ibuprofen, indomethacin, indoprofen,ketoprofen, lorazepam, medroxyprogesterone acetate, megestrol,methoxsalen, methylprednisone, morphine, morphine sulfate, naproxen,nicergoline, nifedipine, niflumic, oxaprozin, oxazepam, oxyphenbutazone,paclitaxel, palperidone, phenindione, phenobarbital, piroxicam,pirprofen, prednisolone, prednisone, procaine, progesterone, propofol,pyrimethamine, risperidone, rofecoxib, sulfadiazine, sulfamerazine,sulfisoxazole, sulindac, suprofen, temazepam, tiaprofenic acid,tilomisole, tolmetic, valdecoxib and ziprasidone.

Further exemplary APIs include, without limitation, Acenocoumarol,Acetyldigitoxih, Anethole, Anileridine, Benzocaine, Benzonatate,Betamethasone, Betamethasone Acetate, Betamethasone Valerate, Bisacodyl,Bromodiphenhydramine, Butamben, Chlorambucil, Chloramphenicol,Chlordiazepoxide, Chlorobutanol, Chlorocresol, Chlorpromazine,Clindamycin Palmitate, Clioquinol, Cortisone Acetate, CyclizineHydrochloride, Cyproheptadine Hydrochloride, Demeclocycline, Diazepam,Dibucaine, Digitoxin, Dihydroergotamine Mesylate, Dimethisterone,Disulfiram, Docusate Calcium, Docusate Sodium, Dihydrogesterone,Enalaprilat, Ergotamine Tartrate, Erythromycin, Erythromycin Estolate,Flumethasone Pivalate, Fluocinolone Acetonide, Fluorometholone,Fluphenazine Enanthate, Flurandrenolide, Guaifenesin, Halazone,Hydrocortisone, Levothyroxine Sodium, Methyclothiazide, Miconazole,Miconazole Nitrate, Nitrofurazone, Nitromersol, Oxazepam, Pentazocine,Pentobarbital, Primidone, Quinine Sulfate, Stanozolol, SulconazoleNitrate, Sulfadimethoxine, Sulfaethidole, Sulfamethizole,Sulfamethoxazole, Sulfapyridine, Testosterone, Triazolam,Trichlormethiazide, and Trioxsalen.

In one embodiment, the dry pharmaceutical composition is reconstitutablein water or an aqueous solution into nanoparticles formed of the PVP-PLAblock co-polymers and comprising the at least one API. The nanoparticlesmay be micelles.

In one embodiment, the dry pharmaceutical composition is freeze dried orspray dried. The composition may also be “bed dried”, i.e. dried on afluidized bed.

In one embodiment, the dry pharmaceutical composition is amorphous.

By “amorphous”, is meant that the API is held is a generally disordered,i.e., non-crystalline state.

In one embodiment, the dry pharmaceutical composition is stable for atleast six months at 40° C.

By “stable”, in the context of a dry composition, is meant that that thedry composition may be stored for a period of time after which it isstill reconstitutable for form for stable nanoparticles.

That period of time may be, e.g. 1 month, 2 months, 3 months, 4 months,5 months, or 6 months. The temperature at which it is stable may, forexample be ambient room temperature, for example about 25° C. It mayalso be 40° C. The composition may be stable over this period at 75%relative humidity. In some embodiments, the compositions are stable for6 months at 40° C. and 75% relative humidity. The stable nanoparticlesso reconstituted, in some embodiments, themselves stable for at leastthree days. The dry composition may be stable for 3 months at 25° C. Thedry composition may be stable for 6 months at 25° C. The dry compositionmay be stable for 3 months at 40° C. The dry composition may be stablefor 6 months at 60° C. The dry composition may be stable for 3 months at25° C.

By “drug loading level” (DLL) as referred to herein is meant the weightratio of drug to the sum of drug and polymer weight in the formulation.

In one embodiment, the dry pharmaceutical composition has a DLL of atleast 10% wt/wt of the at least one API. In one embodiment, the drypharmaceutical composition has a DLL of at least 20% wt/wt of the atleast one API. In one embodiment, the dry pharmaceutical composition hasa DLL of at least 30% wt/wt of the at least one API. DLL may be selectedaccording to the API and according to requirements, and provided thatrequirements for administration are met. The DLL may be 5%, 7.5%, 10%,12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, or greater than 30%.

In one embodiment, the at least one API is hydrophobic.

As used herein, “hydrophobic” means substantially immiscible withaqueous medium.

In one embodiment, the at least one API may be insoluble to sparinglysoluble. In one embodiment, the at least one API has a solubility inwater of 0 g/L to 33 g/L. The API may be insoluble to slightly soluble(i.e., 0 g/L to 10 g/L). In one embodiment, the at least one API has asolubility in water of 0 g/L to 14 g/L. The API may be sparinglysoluble. In one embodiment, the API has a solubility in water of 10 g/Lto 33 g/L.

In one embodiment, the at least one API is selected fromBiopharmaceutical Classification System (BCS) class II and class IV.

In one embodiment, the at least one API comprises an analgesic.

By “analgesic” is meant any member of the group of drugs used to achievereduction or relief of pain. Some examples includeacetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs(NSAIDs), COX-2 inhibitors, opioids, etc.

In one embodiment, the analgesic comprises a nonsteroidalanti-inflammatory drug (NSAID).

By “NSAID” is meant a non-narcotic drug that provides analgesic(pain-killing) and antipyretic (fever-reducing) effects, and, in higherdoses, anti-inflammatory effects. Some examples include aspirin,ibuprofen and naproxen.

In one embodiment, the NSAID comprises flurbiprofen.

In one embodiment, the NSAID comprises a COX-2 inhibitor.

By “COX-2 inhibitor” is meant a drug that selectively inhibits thecyclooxygenase-2 enzyme. In one embodiment, the COX-2 inhibitorcomprises celecoxib.

In one embodiment, the analgesic comprises acetaminophen.

In one embodiment, the at least one API comprises an anesthetic.

By “anesthetic” is meant one of the drugs used to prevent pain, e.g.during surgery. Non-limiting examples of non-opioid anesthetics includeBarbiturates (e.g. Amobarbital, Methohexital, Thiamylal, Thiopental),Benzodiazepines (e.g., Diazepam, Lorazepam, Midazolam), Etomidate,Ketamine, and Propofol. Non-limiting examples of opioid anestheticsinclude Alfentanil, Fentanyl, Remifentanil, Sufentanil, Buprenorphine,Butorphanol, diacetyl morphine, Hydromorphone, Levorphanol, Meperidine,Methadone, Morphine, Nalbuphine, Oxycodone, Oxymorphone, andPentazocine.

In one embodiment, the anesthetic comprises propofol.

In one embodiment, the dry pharmaceutical composition is orallyadministrable.

In one embodiment, the dry pharmaceutical composition is reconstitutablein water to form an essentially clear liquid comprising nanoparticlesformed of the PVP-PLA block copolymers and comprising the at least oneAPI.

In one embodiment, the essentially clear liquid comprises at least 20g/L of the at least one API. In one embodiment, the essentially clearliquid comprises at least 30 g/L of the at least one API. In oneembodiment, the essentially clear liquid comprises at least 40 g/L ofthe at least one API. In one embodiment, the essentially clear liquidcomprises at least 50 g/L of the at least one API.

In one embodiment the dry pharmaceutical composition provides apharmaceutically effective plasma level of the at least one API for atleast 4 hours. In one embodiment the dry pharmaceutical compositionprovides a pharmaceutically effective plasma level of the at least oneAPI for at least 6 fours. In one embodiment the dry pharmaceuticalcomposition provides a pharmaceutically effective plasma level of the atleast one API for at least 8 fours. In one embodiment the drypharmaceutical composition provides a pharmaceutically effective plasmalevel of the at least one API for at least 12 hours.

In some embodiments, the dry pharmaceutical composition comprises atleast two APIs, wherein the block copolymers are as defined as aboveunder Group 2. In some embodiments, the at least two APIs compriseflurbiprofen and celecoxib.

In some embodiments, the dry pharmaceutical composition comprises atleast three APIs, wherein the block copolymers are as defined as aboveunder Group 3. In some embodiments the at least three different APIscomprise at least three of flurbiprofen, celecoxib, acetaminophen, andpropofol. In some embodiments, the at least three different APIscomprise all four of flurbiprofen, celecoxib, acetaminophen, andpropofol

In some embodiments, the dry pharmaceutical composition comprises atleast three APIs, wherein the block copolymers are as defined as aboveunder Group 4. In some embodiments the at least three different APIscomprise at least three of flurbiprofen, celecoxib, acetaminophen, andpropofol. In some embodiments, the at least three different APIscomprise all four of flurbiprofen, celecoxib, acetaminophen, andpropofol

Liquid Pharmaceutical Composition

In one aspect, there is provided a liquid pharmaceutical compositioncomprising a nanoparticles formed of the above-described PVP-PLA blockcopolymers and comprising at least one active pharmaceutical ingredient(API).

In one embodiment, the liquid pharmaceutical composition is anessentially clear liquid.

In one embodiment, the essentially clear liquid is filterable through asterilization filter. A “sterilization filter” will be understood as afilter that achieves filtration required to meet sterility requirements.For example, such a filter may have a pore size of 0.45 microns or 0.2microns.

In one embodiment, the essentially clear liquid is parenterallydeliverable. In one embodiment, the essentially clear liquid isinjectable. In one embodiment, the essentially clear liquid isdeliverable by intravenous. In one embodiment, the essentially clearliquid is deliverable by infusion. The essentially clear liquid may bedeliverable parenterally, intravenously, by infusion, intraocularly,intrathecally, intramuscularly, intraperitoneally, or intraspinally.

In one embodiment, the liquid pharmaceutical composition is stable forat least three days at 25° C.

In one embodiment, the liquid pharmaceutical composition provides apharmaceutically effective plasma level of the at least one API within 2minutes. The liquid pharmaceutical composition may provide apharmaceutically effective plasma level within 1 minute, 2 minutes, 5minutes, 10 minutes, 20 minutes, or 30 minutes.

By “pharmaceutically effective plasma level” is meant an amount of theAPI that, when in plasma, is sufficient to achieve desired therapeuticefficacy. This level can vary depending, for example, on the API, thedisease, disorder, and/or symptoms of the disease or disorder, severityof the disease, disorder, and/or symptoms of the disease or disorder,the age, weight, and/or health of the patient to be treated.

In one embodiment a pharmaceutically effective plasma level of the APIis maintained for at least 4 fours. In one embodiment a pharmaceuticallyeffective plasma level of the at least one API is maintained for atleast 6 fours. In one embodiment a pharmaceutically effective plasmalevel of the at least one API is maintained for at least 8 fours. In oneembodiment a pharmaceutically effective plasma level of the at least oneAPI is maintained for at least 12 hours.

In one embodiment, the liquid pharmaceutical composition furthercomprising a pharmaceutically acceptable diluent, excipient, or carrier.“Pharmaceutically acceptable” refers to additives which are nontoxicwhen administered to a patient in an amount sufficient to provide atherapeutic effect of the API, and which do not destroy the biologicalactivity of the at least one API. “Diluent, excipient, or carrier” willbe understood as an additive having substantially no pharmacologicalactivity of its own.

In one embodiment, the at least one API is hydrophobic.

In one embodiment, the at least one API may be insoluble to sparinglysoluble. In one embodiment, the at least one API has a solubility inwater of 0 g/L to 33 g/L. The API may be insoluble to slightly soluble(i.e., 0 g/L to 10 g/L). In one embodiment, the API has a solubility inwater of 0 g/L to 14 g/L. The API may be sparingly soluble. In oneembodiment, the API has a solubility in water of 10 g/L to 33 g/L.

In one embodiment, the at least one API is selected fromBiopharmaceutical Classification System (BCS) class II and class IV.

In one embodiment, the at least one API comprises an analgesic.

In one embodiment, the analgesic comprises a nonsteroidalanti-inflammatory drug (NSAID).

In one embodiment, the NSAID comprises flurbiprofen.

In one embodiment, the NSAID comprises a COX-2 inhibitor.

In one embodiment, the COX-2 inhibitor comprises celecoxib.

In one embodiment, the analgesic comprises acetaminophen.

In one embodiment, the at least one API comprises an anesthetic.

In one embodiment, the anesthetic comprises propofol.

In one embodiment, the liquid pharmaceutical composition comprises atleast 20 g/L of the at least one API. In one embodiment, the liquidpharmaceutical composition comprises at least 30 g/L of the at least oneAPI. In one embodiment, the liquid pharmaceutical composition comprisesat least 40 g/L of the at least one API. In one embodiment, the liquidpharmaceutical composition comprises at least 50 g/L of the at least oneAPI.

In some embodiments, the liquid pharmaceutical composition comprises atleast two APIs, wherein the block copolymers are as defined as aboveunder Group 2. In some embodiments, the at least two APIs compriseflurbiprofen and celecoxib.

In some embodiments, the liquid pharmaceutical composition comprises atleast three APIs, wherein the block copolymers are as defined as aboveunder Group 3. In some embodiments the at least three different APIscomprise at least three of flurbiprofen, celecoxib, acetaminophen, andpropofol. In some embodiments, the at least three different APIscomprise all four of flurbiprofen, celecoxib, acetaminophen, andpropofol

In some embodiments, the liquid pharmaceutical composition comprises atleast three APIs, wherein the block copolymers are as defined as aboveunder Group 4. In some embodiments the at least three different APIscomprise at least three of flurbiprofen, celecoxib, acetaminophen, andpropofol. In some embodiments, the at least three different APIscomprise all four of flurbiprofen, celecoxib, acetaminophen, andpropofol

Haemolysis

In one aspect, the above-described block copolymers may find applicationin mitigation of haemolytic effects.

In one aspect, the above-described block copolymers may find applicationin mitigation of haemolytic activity of a cargo molecule. The cargo maybe a small or large molecule, such as an API.

By “haemolytic activity” or “haemolytic effects” will be understood thepropensity for a particular molecule or formulation to cause haemolysis,i.e. lysis of red blood cells (RBCs). These may be mammalian RBCs, e.g.,human red blood cells. The propensity to cause haemolysis may be may bedetermined in vitro, for example, using RBCs derived from blood, forexample, derived from whole human blood. An example in vitro test is themethod followed in Example 5. For example suspended RBCs isolated fromwhole human blood may be mixed with non-formulated cargo molecules ortest formulations comprising the cargo molecule at a given finalconcentration with respect to the cargo molecule incubated at 37° C. for60 minutes, and centrifuged to remove intact RBCs. Absorbance at 540 nmmay then be measured and compared against control samples, e.g. for 0and 100% haemolysis. The in vitro test may be one established to providean indication of the haemolytic potential of the cargo molecule or thehaemo-protective potential of the formulation in vivo.

Where mitigation of haemolysis is mentioned for a particular formulatedcargo molecule (i.e. formulated with PVP-PLA block co-polymer), it willbe understood that this means that there is a degree of protectionafforded by the formulation (the haemo-protective potential) to RBCsagainst cargo molecule induced haemolysis which protection may beexpressed as a percentage of that caused by the cargo molecule in anunformulated or conventionally formulated state. For example, the degreeof haemo-protection afforded to RBCs by a PVP-PLA block co-polymerformulation of FLU against the haemolytic activity of unformulated orconventionally formulated FLU may be calculated as:100%−((percent haemolysis observed for PVP-PLA FLU formulation)+(percenthaemolysis observed for unformulated or conventionally formulatedFLU)×100%).

Thus, in an example scenario in which unformulated FLU at a finalconcentration 5 g/L causes 90% haemolysis and PVP-PLA FLU causes 7%(i.e. similar to that of the negative control), the degree of protectionwould be 100%−(7/90×100%)=92%.

By “unformulated state” will be understood the molecule in the absenceof the PVP-PLA block copolymers described herein. Likewise,“conventionally formulated” will be understood as some other formulationof the molecule that does not include the PVP-PLA block copolymersdescribe here.

In one embodiment, there is provided a use of the above-described blockcopolymers for mitigation of haemolytic activity of a cargo molecule,such as an API. In one embodiment there is provided a use of theabove-described block copolymers for mitigation of the heamolyticpotential of a cargo molecule, such as an API, to negative controllevels. In some embodiments, the negative control levels will beunderstood to be the degree of haemolysis caused by addition of thenegative control solution. An example is the negative control describedin Example 5. In one embodiment, the block copolymers may be as definedfor Group 1. In one embodiment, the block copolymers may be as definedfor Group 2. In one embodiment, the block copolymers may be as definedfor Group 3. In one embodiment, the block copolymers may be as definedfor Group 4. In one embodiment, the degree of protection, as definedabove, is at least 50%. In one embodiment, the degree of protection isat least 60%. In one embodiment, the degree of protection is at least70%. In one embodiment, the degree of protection is at least 80%. In oneembodiment, the degree of protection it at least 90%. In one embodiment,the degree of protection it at least 92%. In one embodiment, the degreeof protection it at least 95%.

In one embodiment, there is provided a block copolymer, as describedabove, for use in mitigation of haemolytic activity of a cargo molecule,such as an API. In one embodiment there is provided a block copolymerfor mitigation of the heamolytic potential of a cargo molecule, such asan API, to negative control levels. In some embodiments, the negativecontrol levels will be understood to be the degree of haemolysis causedby addition of the negative control solution. An example is the negativecontrol described in Example 5. In one embodiment, the block copolymersmay be as defined for Group 1. In one embodiment, the block copolymersmay be as defined for Group 2. In one embodiment, the block copolymersmay be as defined for Group 3. In one embodiment, the block copolymersmay be as defined for Group 4. In one embodiment, the degree ofprotection, as defined above, is at least 50%. In one embodiment, thedegree of protection is at least 60%. In one embodiment, the degree ofprotection is at least 70%. In one embodiment, the degree of protectionis at least 80%. In one embodiment, the degree of protection it at least90%. In one embodiment, the degree of protection it at least 92%. In oneembodiment, the degree of protection it at least 95%.

In one embodiment, there is provided a method of mitigating haemolyticactivity of a cargo molecule, such as an API, the method comprising thesteps of: mixing block copolymers described above with the API to form aliquid pharmaceutical composition, said liquid pharmaceuticalcomposition exhibiting reduced or no hemolytic activity compared to theAPI in an non-formulated stated. In one embodiment, the block copolymersmay be as defined for Group 1. In one embodiment, the block copolymersmay be as defined for Group 2. In one embodiment, the block copolymersmay be as defined for Group 3. In one embodiment, the block copolymersmay be as defined for Group 4. In one embodiment, the degree ofprotection, as defined above, is at least 50%. In one embodiment, thedegree of protection is at least 60%. In one embodiment, the degree ofprotection is at least 70%. In one embodiment, the degree of protectionis at least 80%. In one embodiment, the degree of protection it at least90%. In one embodiment, the degree of protection it at least 92%. In oneembodiment, the degree of protection it at least 95%.

In one embodiment, the above-described dry pharmaceutical compositionexhibits mitigated haemolytic effects for the API, when reconstituted toform a liquid pharmaceutical composition. In one embodiment, theabove-described dry pharmaceutical composition exhibits mitigatedhaemolytic activity for the API, when reconstituted to form a liquidpharmaceutical composition, e.g. compared to the API alone. In oneembodiment, the block copolymers may be as defined for Group 1. In oneembodiment, the block copolymers may be as defined for Group 2. In oneembodiment, the block copolymers may be as defined for Group 3. In oneembodiment, the block copolymers may be as defined for Group 4. In oneembodiment, the degree of protection, as defined above, is at least 50%.In one embodiment, the degree of protection is at least 60%. In oneembodiment, the degree of protection is at least 70%. In one embodiment,the degree of protection is at least 80%. In one embodiment, the degreeof protection it at least 90%. In one embodiment, the degree ofprotection it at least 92%. In one embodiment, the degree of protectionit at least 95%.

In one embodiment, the above-described liquid formulation exhibitsmitigated haemolytic activity for the API. In one embodiment, theabove-described liquid formulation exhibits mitigated haemolyticactivity for the API, e.g. compared to the API alone. In one embodiment,the block copolymers may be as defined for Group 1. In one embodiment,the block copolymers may be as defined for Group 2. In one embodiment,the block copolymers may be as defined for Group 3. In one embodiment,the block copolymers may be as defined for Group 4. In one embodiment,the degree of protection, as defined above, is at least 50%. In oneembodiment, the degree of protection is at least 60%. In one embodiment,the degree of protection is at least 70%. In one embodiment, the degreeof protection is at least 80%. In one embodiment, the degree ofprotection it at least 90%. In one embodiment, the degree of protectionit at least 92%. In one embodiment, the degree of protection it at least95%.

In one embodiment of the above, the API comprises celecoxib. In some ofthese embodiments, the DLL of the celecoxib is 5% to 15%. In oneembodiment, the DLL of the celecoxib is about 10%.

In one embodiment of the above, the API comprises acetaminophen. In someof these embodiments, the DLL of the acetaminophen is 13% to 23%. In oneembodiment, the DLL of the acetaminophen is about 18%.

In the above, the API may be one that causes haemolysis in anunformulated or conventionally formulated state. In some embodiments,the level of haemolysis caused by the API may be a level that precludesits administration to a subject. The API may be one that is known tocause haemolysis, e.g. when administered (e.g. parenterally) to asubject in an unformulated stated. The API may be an API that, in itsunformulated state, causes more than 10% haemolysis of RBCs in the testset forth in Example 5. It will be understood that an API that “causeshaemolysis” may do so at a desired level of administration in anunformulated or conventionally formulated state, and not necessarily atall (or to the same extend) at other levels in an unformulated orconventionally formulated state. One example API that causes haemolysisin an unformulated stated is flurbiprofen.

In some embodiments of the above, the API is flurbiprofen. In some ofthese embodiments, the DLL of the flurbiprofen is 15 to 25%. In oneembodiment, the DLL of the flurbiprofen is about 20%.

Method of Forming Pharmaceutical Compositions

In one aspect, there is provide a method of forming a pharmaceuticalcomposition comprising mixing the above-described block copolymers withat least one API to form nanoparticles comprising the at least one API.

In one embodiment, the at least one API comprises at least two APIs, andthe block co-polymers are as defined above under Group 2. In someembodiments, the at least two APIs comprise flurbiprofen and celecoxib.

In one embodiment, the at least one API comprises at least three APIs,and the block co-polymers are as defined above under Group 3. In someembodiments the at least three different APIs comprise at least three offlurbiprofen, celecoxib, acetaminophen, and propofol. In someembodiments, the at least three different APIs comprise all four offlurbiprofen, celecoxib, acetaminophen, and propofol.

In one embodiment, the at least one API comprises at least three APIs,and the block co-polymers are as defined above under Group 4. In someembodiments the at least three different APIs comprise at least three offlurbiprofen, celecoxib, acetaminophen, and propofol. In someembodiments, the at least three different APIs comprise all four offlurbiprofen, celecoxib, acetaminophen, and propofol.

In one embodiment, the above-described methods may comprise a step ofdrying the pharmaceutical composition.

In some embodiments involving a plurality of APIs, the plurality of APIsmay be mixed together with the copolymers.

Alternative, the method may comprise separately mixing each API with anamount of the block copolymer prior to combining them. These embodimentsmay comprise an additional step of incubating the two populations ofnanoparticles so-formed together for sufficient time for an exchange ofAPIs to take place as the mixture equilibrates.

Delivery Methods, Uses, and Kits

In one aspect, there is provided a method of delivering at least oneactive pharmaceutical ingredient (API) to a subject in need thereof,comprising administering the above-described dry pharmaceuticalcomposition to the subject.

In one embodiment, the administering is orally administering.

In one aspect, there is provided a method of delivering at least oneactive pharmaceutical ingredient (API) to a subject in need thereof,comprising administering the above-described liquid pharmaceuticalcomposition to the subject.

In one embodiment, said administering comprises injecting, parenterallyadministering, intravenously administrating, infusing, intraocularlyadministering, intrathecally administering, intramuscularlyadministering, intraperitoneally administering, or intraspinallyadministering.

In one embodiment, the pharmaceutically effective plasma level ismaintained for at least 4 hours. In one embodiment, the pharmaceuticallyeffective plasma level is maintained for at least 6 hours. In oneembodiment, the pharmaceutically effective plasma level is maintainedfor at least 8 hours. In one embodiment, the pharmaceutically effectiveplasma level is maintained for at least 12 hours.

In one embodiment, the subject is in pain, and the at least one APIcomprises an analgesic. In one embodiment, the analgesic comprises anNSAID. In one embodiment, the NSAID i comprises s flurbiprofen. In oneembodiment, the NSAID comprises celecoxib.

In one embodiment, the analgesic comprises acetaminophen.

In one embodiment, the subject is in need of anesthesia and the at leastone API is an anesthetic. In one embodiment, the anesthetic is propofol.

In one aspect, there is provided the above-described dry pharmaceuticalcomposition or the above-described liquid pharmaceutical composition foruse in delivery of at least one active pharmaceutical ingredient (API)to a subject.

In one embodiment, the composition is for use in treatment of pain inthe subject, wherein the at least one API comprises an analgesic.

In one embodiment, the analgesic comprises an NSAID.

In one embodiment, the NSAID comprises flurbiprofen.

In one embodiment, the NSAID comprises celecoxib.

In one embodiment, the analgesic comprises acetaminophen.

In one embodiment, the composition is for use in providing anesthesia tothe subject, wherein the API comprises an anesthetic.

In one embodiment, the anesthetic is propofol.

In one aspect, there is provided a kit comprising the above-describeddry pharmaceutical composition or the above-described liquidpharmaceutical composition, and instructions for use in delivery of atleast one active pharmaceutical ingredient (API) to a subject.

In one aspect, there is provided a kit comprising the above-describeddry pharmaceutical composition or the above-described liquidpharmaceutical composition, and instructions for use in delivery of atleast one active pharmaceutical ingredient (API) for treatment of painin a subject.

In one embodiment the at least one API comprises flurbiprofen,celecoxib, or acetaminophen.

In one aspect, there is provided a kit comprising the above-describeddry pharmaceutical composition or the above-described liquidpharmaceutical composition, and instructions for use in delivery of atleast one active pharmaceutical ingredient (API) for providinganesthesia to a subject.

In one embodiment, the at least one API comprises propofol.

Production Methods

In another aspect, there is provided a method of preparing PVP-PLA blockcopolymers as defined in Formula I:

wherein: x is an initiator alcohol having a boiling point greater than145° C., n is, on average, from 20 and 40, and m is, on average, from 10and 40, wherein the block copolymers have a number average molecularweight (Mn) of at least 3000 Da, the method comprising: initiatingpolymerization of D,L-Lactide from the initiator alcohol x to formpoly(lactic acid) (PLA), adding a xanthate to the PLA to form a PLAmacroinitiator, and polymerizing NVP, by controlled polymerization, ontothe PLA macroinitiator to form the block copolymer compound of FormulaI.

In one embodiment, the controlled polymerization is controlled radicalpolymerization.

In one embodiment, the PVP-PLA block copolymer are as defined herein.

In one embodiment, the PVP-PLA block copolymer are as defined aboveunder Group 1.

In one embodiment, the PVP-PLA block copolymer are as defined aboveunder Group 2.

In one embodiment, the PVP-PLA block copolymer are as defined aboveunder Group 3.

In one embodiment, the PVP-PLA block copolymer are as defined aboveunder Group 4.

In one embodiment, the polymerization of the D,L-Lactide is by anorganocatalytic coordination-insertion polymerization. In oneembodiment, the catalyst for the polymerization of the D,L-Lactide is4-dimethylaminopyridine (DMAP). In one embodiment, the polymerization ofthe D,L-Lactide takes place at a temperature of at least 60° C. to 90°C. In one embodiment, the polymerization of the D,L-Lactide takes placefor at least 24 hours. In one embodiment, the polymerizing of theD,L-Lactide takes place for at least 48 hours. In one embodiment, thepolymerizing of the D,L-Lactide takes place for at least 60 hours.

In one embodiment, the polymerization of the D,L-Lactide is by anorganocatalytic coordination-insertion polymerization. In oneembodiment, the catalyst for the polymerization of the D,L-Lactide is orstannous octoate (Sn(Oct)₂). In one embodiment, the polymerization ofthe D,L-Lactide takes place at a temperature of at least 135° C. to 160°C. In one embodiment, the polymerizing of the D,L-Lactide takes placefor at least 24 hours. In one embodiment, the polymerizing of theD,L-Lactide takes place for at least 48 hours. In one embodiment, thepolymerizing of the D,L-Lactide takes place for at least 60 hours.

In one embodiment, the catalyst for the polymerizing of the NVP isazobisisobutyronitrile (AIBN). In one embodiment, the polymerizing ofthe NVP takes place at a temperature of at least 70° C. to 90° C. In oneembodiment, the polymerizing of the NVP takes place for at least 24hours. In one embodiment, the polymerizing of the NVP takes place for atleast 48 hours. In one embodiment, the polymerizing of the NVP takesplace for at least 60 hours.

In one embodiment, the method further comprises removing the xanthate.

In one embodiment, the method further comprises adding a functionalmoiety.

By “functional moiety” is meant a molecular modification or additionthat provides a desired functional activity or reactivity. The“functional moiety” may be a “targeting moiety” designed to target theensuing nanoparticles formed of the block copolymers to a particularcell type, e.g. by targeting a particularly cell surface protein orreceptor. The addition of a functional moiety may result innanoparticles that are functionalized or decorated. For example,functional moieties may include a dye, a tracer, or a terminalfunctional group.

In one embodiment, the functional moiety comprises a targeting moiety.

By “targeting moiety” is meant any chemical compound, including, e.g., apeptide or nucleic acid, that imparts a targeting function to micellesformed of the block-copolymers to which it is attached. Targetingmoieties may, for example, have affinity for particularly cell surfaceproteins or receptors. This may be characteristic of a particular organor cell type. In one embodiment, the targeting moiety comprises albumin,folate, or an aptamer. By “aptamer” is meant a single-stranded DNA orRNA (ssDNA or ssRNA) molecules that can bind to a pre-selected target,such as a protein or peptide, with high affinity and specificity.

EXAMPLES Introduction to Examples 1 & 2

PVP-PLA technology can be used for formulation of drugs, e.g. with doselimiting solubility in water. The technology has the ability to formmicelles independently of the pH when the polymer concentration in wateris above the critical micellar concentration (CMC). The micelles aredisrupted when the polymer concentration decreases below the CMC.Following this principle, a formulation comprising reconstituted PVP-PLAmicelles will begin releasing its drug content, e.g., upon injectioninto blood. PVP-PLA technology remains challenging because ofinefficient synthesis and polydispersity, and because of lack offlexible delivery platforms having the ability to formulate a variety ofdrugs and/or entrap them at sufficiently high concentration (i.e., drugloading level or DLL).

New PVP-PLA copolymers or methods of production were sought that wouldprovide relevant physical or chemical properties, desired yield,efficiency of synthesis, low polydispersity, ease production, desiredflexibility in formulating a range of drugs, and/or high DLL. Two mainapproaches were used to attempt to improve the synthesis of the PVP-PLAblock copolymer.

In the first approach, the PVP-PLA was prepared using apolyvinylpyrrolidone with a terminal hydroxyl group (termed “PVP-OH”) asa macro initiator followed by (i) an organometalliccoordination-insertion polymerization (Scheme 1A), (ii) an anionicpolymerization (Scheme 1B), or (iii) an organocatalyticcoordination-insertion polymerization (see Scheme 1C) of the D,L-Lactide[1]. This approach will be subsequently referred to as the “PVP-OHapproach”. Scheme 1 shows each synthesis route for one type of catalyst,one solvent, and one specific temperature. However, each synthesis routewas tested in two or three different solvents, using two types ofcatalysts and at two different temperatures. In total, 8 to 12 synthesesper route were carried out.

In the second approach, the PVP-PLA was produced starting with thepreparation of the poly(D,L-lactide) with a terminal hydroxyl group(termed “PLA-OH”) and the PLA-OH was used as a macro chain transferagent to polymerize the N-vinyl-2-pyrrolidinone (NVP). The preparationof the PLA-OH was performed following either (i) an organocatalyticcoordination-insertion polymerization (see Scheme 2A-1) or (ii) anorganometallic coordination-insertion polymerization (see Schemes 2B-1and 2C-1). The PLA-OH obtained was converted to a macro chain transferagent by substituting the terminal hydroxyl group by an O-ethyl xanthategroup. The substitution of the hydroxyl group required two steps asillustrated in Scheme 2. After the substitution, the resulting macrochain transfer agent of PLA was used to polymerize the NVP (see schemes2A-4, 2B-4 and 2C-4). This second approach will be subsequently referredto as the “PLA-OH approach”.

Example 1: The PVP-OH Approach

PVP-PLA was obtained by using PVP-OH as a macro initiator for thepolymerization of D,L-lactide. PVP-OH used during this project is acommercial polymer from Polysciences (Cat. Number 16693, Lot Number652063 and Mw 2500). However, PVP-OH can also be made by a radicalpolymerization of N-vinyl-2-pyrrolidinone (NVP) in the presence of2-isopropoxyethanol (IPE) or mercaptoethanol or functionalizeddisulfides as chain transfer agent (CTA) [2, 3]. Independently of theCTA, most of the PVP chains obtained had one or two chain transferagents as a terminal group. The obtained polymer was a mixture ofOH-PVP-OH, PVP-OH and PVP at different proportions. However, theproportion of PVP-OH can be increased by the type of chain transferagent used and the experimental conditions of the polymerization. Thesynthesis of PVP-OH with a controlled molecular weight andpolydispersity index (PDI) remains challenging.

Organometallic Coordination-Insertion Polymerization of PVP-PLA

The organometallic coordination-insertion polymerization of PVP-PLA wasperformed in the presence of either dibutyl tin dilaurate (DBTDL) ordibutyl tin oxide (DBTO) as catalyst. Scheme 3 shows the synthesis routefor the preparation of PVP-PLA using DBTDL as catalyst in differentexperimental conditions and solvents.

Procedure of the Synthesis

A required amount of PVP-OH (previously dried using toluene as solvent)was dissolved in N-Methyl-2-pyrrolidone (NMP) and then a certainquantity of dibutyl tin dilaurate was added to the mixture. After thedispersion of the DBTDL, a required ratio of D,L-lactide (the compoundis previously dried after purification by recrystallization from ethylacetate) was added to the mixture. The obtained reaction mixturesolution was stirred under argon atmosphere for 1 h and then put at 130°C. and kept under argon atmosphere for another 4 hrs. The polymerizationwas left for 20 hrs more and then cooled to room temperature before theprecipitation in diethyl ether. A white solid product was obtained afterprecipitation.

The cooled solution was added dropwise to a certain amount of diethylether and then the product was collected by filtration. The productobtained was washed with three portions of diethyl ether before beingdried overnight at 40° C. Table 1 shows the amount of raw materials usedfor the preparation of PVP-PLA in the presence of DTBL as catalyst andNMP as solvent.

TABLE 1 Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL)DL-Lactide 144.13 32.00 0.2220 N/A PVP-OH 2500 37.00 0.0148 N/A DBTDL631.56 9.47 0.0150 1.066 NMP 99.13 257.00 2.5926 1.028

Other Experimental Conditions

The synthesis of PVP-PLA by organometallic coordination-insertionpolymerization was repeated under various experimental conditions. Table2 illustrates all the conditions and the amount of raw materials used togenerate the block copolymer of PVP-PLA.

TABLE 2 Mass Temper- Mw used Density ature Time Compounds (g/mol) (g)Mole (g/mL) (° C.) (h) DL-Lactide 144.13 32.00 0.2220 N/A 140 4 PVP-OH2500 37.00 0.0148 N/A DBTDL 631.56 9.47 0.0150 1.066 NMP 99.13 257.002.5926 1.028 DL-Lactide 144.13 16.00 0.1110 N/A 95 24 PVP-OH 2500 19.000.0076 N/A DBTDL 631.56 4.74 0.0075 1.066 Toluene 92.14 130.00 2.59260.865 DL-Lactide 144.13 16.00 0.1110 N/A 75 24 PVP-OH 2500 19.00 0.0076N/A DBTDL 631.56 4.74 0.0075 1.066 THF 72.11 222.25 3.0821 0.889DL-Lactide 144.13 15.00 0.1041 N/A 120 36 PVP-OH 2500 15.00 0.0060 N/ADBTO 248.94 0.50 0.0002 N/A NMP 99.13 257.00 2.5926 1.028

Results

Independent of the experimental conditions used, a very viscous productwas obtained for each case. However, the results from testing ordifferent techniques show that the D,L-Lactide did not react with thePVP-OH as expected. Without being bound by theory, the limitedproportion of PVP-OH may be the main cause of those results. Asmentioned above, it is a challenge to obtain PVP-OH in a proportiongreater than 50% [3]. The product obtained was usually a mixture ofHO-PVP-OH, PVP-OH and PVP. In order to understand the results obtained,it was decided to repeat the synthesis with DBTDL and DBTO in NMP at130° C. and 120° C., respectively. However, the PVP-OH was replaced by acommercial poly(ethylene glycol) monomethyl ether (MePEG-OH) from SigmaAldrich. The MePEG-OH (Cat Number 202509, lot Number MKBS5550V and Mw2000) contains more than 90% of one terminal hydroxyl group incomparison to 50% for PVP-OH. The results obtained with MePEG-OH weremuch better than with PVP-OH except in the case of MePEG-OH—theD,L-Lactide reacted with MePEG-OH but the yield was less than 25%.Moreover, the Mn was much smaller than expected. Based on these results,the organometallic coordination-insertion polymerization from PVP-OH wasnot a sufficiently good method to prepare PVP-PLA for cost-effectivedevelopment of potent drug products that are marketable.

Anionic Polymerization of PVP-PLA

The anionic polymerization of PVP-PLA was performed in the presence ofeither the sodium hydride (NaH) or potassium hydride (KH) as catalyst.Scheme 4 shows the resulting synthetic route for the preparation ofPVP-PLA using NaH as catalyst in different experimental conditions.

Procedure of the Synthesis

A required amount of PVP-OH was dissolved in N-Methyl-2-pyrrolidone(NMP) and then a certain quantity of NaH was added to the mixture. Afterthe dispersion of the NaH, a required ratio of D,L-lactide (previouslydried and purified by recrystallization from ethyl acetate) was added tothe mixture. The mixture obtained was stirred under nitrogen atmospherefor 1 h and then put at 130° C. and kept under nitrogen atmosphere foranother 4 hrs. The polymerization was left for 20 hrs and then cooled toroom temperature before precipitation in diethyl ether.

The cooled solution was added dropwise to an amount of diethyl ether andthen the product was collected by filtration. The product obtained waswashed with three portions of diethyl ether before being dried overnightat 40° C. Table 3 shows the amounts of raw materials used for thepreparation of PVP-PLA in the presence of NaH as catalyst and NMP assolvent.

TABLE 3 Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL)DL-Lactide 144.13 32.00 0.2220 N/A PVP-OH 2500 37.00 0.0148 N/A NaH24.00 0.600 0.0150 0.600 NMP 99.13 257.00 2.5926 1.028

Other Experimental Conditions

As performed in the previous synthetic method, the synthesis of PVP-PLAby anionic polymerization was repeated under various experimentalconditions. Table 4 illustrates all the conditions and the amounts ofraw materials used to generate the PVP-PLA.

TABLE 4 Mass Temper Mw used Density ature Time Compounds (g/mol) (g)Mole (g/mL) (° C.) (h) DL-Lactide 144.13 32.00 0.2220 N/A RT 24 PVP-OH2500 37.00 0.0148 N/A NaH 24.00 0.600 0.0150 0.600 THF 72.11 222.253.0821 0.889 DL-Lactide 144.13 32.00 0.2220 N/A 50 24 PVP-OH 2500 37.000.0148 N/A NaH 24.00 0.600 0.0150 0.600 THF 72.11 222.25 3.0821 0.889DL-Lactide 144.13 32.00 0.2220 N/A RT 24 PVP-OH 2500 37.00 0.0148 N/A KH40.11 1.00 0.0250 N/A THF 72.11 222.25 3.0821 0.889 DL-Lactide 144.1332.00 0.2220 N/A 50 24 PVP-OH 2500 37.00 0.0148 N/A KH 40.11 1.00 0.0250N/A THF 72.11 222.25 3.0821 0.889 DL-Lactide 144.13 32.00 0.2220 N/A130  24 PVP-OH 2500 37.00 0.0148 N/A KH 40.11 1.00 0.0250 N/A NMP 99.13257.00 2.5926 1.028

Results

Independent of the experimental conditions used, a white solid wasobtained in each case. The results from different techniques show thatthe D,L-Lactide reacted partially with the PVP-OH only in the case ofthe synthesis with NaH in THF at room temperature. The yield obtainedfor this synthesis was always below 30%. These results suggest that thePVP-OH sodium salt is not as efficient as a macro initiator since 50%yield was expected instead of 30% [3]. The method also led to theproduction of a very small proportion of a homopolymer of PLA-OH, butenough to generate a bimodal micelle size distribution. The bimodalmicelle size distribution is not suitable for parenteral formulations,especially if one of the sizes obtained is bigger than 500 nm. Moreover,whatever the purification process used, it is difficult to obtain onlyPVP-PLA with the expected molecular weight. For this reason, the finalproduct contains, at different proportions, four polymers (PVP-PLA,PLA-OH, HO-PVP-OH and PVP). The main product remains PVP-PLA, but thismethod did not allow the control of molecular weight. The Mw is muchsmaller than expected. Based on the above noted results, the anionicpolymerization was also not a sufficiently good method to preparePVP-PLA for cost-effective development of potent drug products that aremarketable.

Organocatalytic Coordination-Insertion Polymerization of PVP-PLA

The organocatalytic coordination-insertion polymerization method wasattempted to produce the PVP-PLA in the presence1,3-dimesitylimidazolinium chloride (DMIC) as catalyst. This type ofN-heterocyclic carbene compound is known to produce a livingring-opening polymerization (ROP). However, DMIC compound has never beenuse in the polymerization of PLA when PVP-OH is used as a macroinitiator. Furthermore, DMIC is not available commercially and needs tobe prepared. The preparation of DMIC requires three steps and each stepled to a yield greater than 85%. Schemes 5 to 7 illustrate the synthesisroutes for the preparation of the DMIC. Table 5 to 7 show the amount ofraw materials used for each step.

Step 1: Synthesis of DMEDI

Scheme 5 shows the Synthesis route of the first step of the preparationof DMEDI.

TABLE 5 Raw Materials for Synthesis of DMEDI Mw Mass used DensityCompounds (g/mol) (g) Mole (g/mL) 2,4,6-trimethylaniline 135.21 40.50.3000 0.963 Glyoxal 58.04 21.7 0.150 0.400 Isopropyl alcohol 60.100.600 0.0150 0.785

Step 2: Synthesis of DMEDADH

Scheme 6 depicts the synthesis route of the second step of thepreparation of DMEDADH.

TABLE 6 Raw Materials for the Synthesis of DMEDADH. Mw Mass used DensityCompounds (g/mol) (g) Mole (g/mL) DMEDI 292.40 36.5 0.125 N/A NaBH₄37.84 18.9 0.500 N/A HCl 36.46 25.2 0.250 N/A

Step 3: Synthesis of DMIC

Scheme 7 depicts the synthesis route of the third step which led to thepreparation of DMIC.

TABLE 7 Raw Materials for the Synthesis of DMIC. Mw Mass used DensityCompounds (g/mol) (g) Mole (g/mL) DMEDADH 369.60 18.5 0.050 N/A Triethylorthoformate 148.20 22.3 0.150 0.891

Procedure of the Synthesis

The procedure for the preparation of DMIC has been described by Delaudeet al. [4]. As mentioned above, DMIC has not been used in thepreparation of PVP-PLA.

Synthesis of PVP-PLA Using DMIC as a Catalyst

The preparation of PVP-PLA using DMIC as a catalyst and THF or DMSO assolvent is presented in Scheme 8.

The preparation of the PVP-PLA in the presence of DMIC began with thedissolution of an amount of PVP-OH in THF or DMSO and then a quantity ofDMIC was added to the mixture. After the dissolution of the DMIC, arequired ratio of D,L-lactide (previously dried and purified byrecrystallization from ethyl acetate) was added to the mixture. Theobtained mixture was stirred under an argon atmosphere for 1 h and thenput at 130° C. and kept under the argon atmosphere for another 4 hrs.The polymerization was left for 20 hrs more and then cooled to roomtemperature before the precipitation in diethyl ether.

The cooled solution was added dropwise to an amount of diethyl ether andthen the product was collected by filtration. The product obtained waswashed with three portions of diethyl ether before being dried overnightat 40° C. Table 8 shows the amount of raw materials used for thepreparation of PVP-PLA in the presence of DTBL as catalyst and NMP assolvent.

TABLE 8 Raw Material for the Synthesis of PVP-PLA in the presence ofDMIC Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL) DL-Lactide144.13 32.00 0.2220 N/A PVP-OH 2500 37.00 0.0148 N/A DMIC 342.91 5.140.0150 N/A THF 72.11 222.25 3.0821 0.889

TABLE 9 Raw Material for the Synthesis of PVP-PLA in the presence ofDMIC Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL) DL-Lactide144.13 32.00 0.2220 N/A PVP-OH 2500 37.00 0.0148 N/A DMIC 342.91 5.140.0150 N/A DMSO 78.13 200.00 2.5598 1.100

Results

The data obtained from different techniques show that the D,L-Lactidereacted partially with the PVP-OH in both solvents. However, the yieldfor each synthesis was around 25%. This method seemed promising and itsoptimisation could lead to higher yield. Despite the low yield, thismethod led to a better control of the molecular weight. Results obtainedsuggest that the organocatalytic coordination-insertion polymerizationcould be a good method to prepare PVP-PLA for cost-effective developmentof potent drug products that are marketable.

Example 2: The PLA-OH Approach

As illustrated in Scheme 2, the PVP-PLA was obtained by usingD,L-Lactide as raw material to generate the PLA-OH either by anorganocatalytic coordination-insertion polymerization (see Scheme 2A-1)or by an organometallic coordination-insertion polymerization (seeSchemes 2B-1 and 2C-1). Thus, the PLA-OH obtained was then converted toa macro chain transfer agent by substituting the terminal hydroxyl groupwith an O-ethyl xanthate group. The new macro chain transfer agentobtained was used to initiate the polymerization of NVP. D,L-Lactideused during this project was from Sigma Aldrich (Cat Number 303143, LotNumber STBF0369V and Mw 144.13) and was dried and purified byrecrystallization from ethyl acetate before being used.

The idea behind the PLA-OH approach was to take advantage of theknowledge acquired from the lack of success with the PVP-OH approach togenerate a PVP-PLA with a high yield as well as a high purity. It isdesirable to avoid having a material with three different homopolymersremaining before the next polymerization step, as observed in the caseof the preparation of PVP-OH. For that reason, PLA-OH was prepared firstby avoiding using the anionic polymerization method. For that reason,two different coordination-insertion methods were selected to test thetactic of PLA-OH approach.

Organocatalytic Coordination-Insertion Polymerization of PLA-OH

The organocatalytic coordination-insertion polymerization of PLA-OH wasperformed in the presence of 4-dimethylaminopyridine (DMAP) as catalystand isopropyl alcohol (IPA) as initiator. Scheme 9 shows the syntheticroute for the preparation of PLA-OH in NMP at 80° C.

Procedure of the Synthesis

PLA-OH is synthesized via ring opening polymerization (ROP) ofD,L-lactide using an amount of IPA as initiator and DMAP as thecatalyst. The procedure began by putting the D,L-lactide (recrystallizedfrom ethyl acetate before used) in a dry round flask under an argonatmosphere. NMP and IPA were added and followed by the addition of DMAPin the reaction flask. The reaction mixture was heated at 80° C. for 24hrs and kept under an argon atmosphere during that period of time. Aftercooling to room temperature, the obtained crude product was dissolved inDCM and precipitated from hexanes. The precipitated polymer wascollected and dissolved again in DCM followed by another precipitationfrom hexanes. Finally, the collected PLA-OH was dried under vacuum at40° C. for 48 hrs. Table 10 illustrates the quantity of reactants usedfor the synthesis of PLA-OH.

TABLE 10 Raw Materials Used for the Synthesis of PLA-OH in the Presenceof DMAP Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL)DL-Lactide 144.13 22.00 0.1526 N/A Isopropyl alcohol 60.10 1.02 0.01700.785 DMAP 122.17 1.20 0.0099 N/A NMP 99.13 128.50 1.2962 1.028

Results

The data obtained from the preparation of PLA-OH show that theD,L-Lactide polymerized in the presence of DMAP and IPA. The yieldobtained for the synthesis was close to 60%. As for DMIC, this methodseems promising and its optimisation could lead to higher yield. Despitethe low yield, this method also led to a better control of the molecularweight. Results obtained show that the organocatalyticcoordination-insertion polymerization of PLA-OH has the potential togenerate potent, inexpensive and marketable drug products.

Organometallic Coordination-Insertion Polymerization of PLA-OH

Two organometallic coordination-insertion polymerization methods wereused to produce the PLA-OH. For each method a different catalyst wasused. Schemes 10 and 11 show the synthesis route in the presence ofDBTDL or Sn(Oct)₂ as catalyst. As illustrated, the other main differencebetween the two syntheses is that NMP was used as solvent for thesynthesis with DBTDL while that performed in the presence of Sn(Oct)₂ isin bulk. The temperature required for both syntheses was very close(145° C. and 150° C., respectively). Tables 11 and 12 illustrate thequantity of reactants required for each polymerization.

Scheme 10 shows the synthesis route for the preparation of PLA-OH usingDBTDL as catalyst in NMP at 145° C.

TABLE 11 Raw Materials Used for the Synthesis of PLA-OH in the Presenceof DBTDL Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL)DL-Lactide 144.13 21.00 0.1457 N/A Diethylene glycol 134.17 1.59 0.01190.999 monoethyl ether DBTDL 631.57 0.21 0.0003 1.066 NMP 99.13 10.280.1037 1.028

Scheme 11 shows the synthesis route for the preparation of PLA-OH inbulk at 145° C. and using Sn(Oct)₂ as catalyst.

TABLE 12 Raw Materials Used for the Synthesis of PLA-OH in the Presenceof Sn(Oct)₂ Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL)DL-Lactide 144.13 27.20 0.1457 N/A Diethylene glycol 134.17 1.87 0.01390.999 monoethyl ether Sn(Octc)₂ 405.12 0.12 0.0003 1.066

Procedure of the Synthesis

PLA-OH was synthesized via the ROP of D,L-lactide using in that casediethylene glycol monoethyl ether (DEGMEE) as initiator and either DBTDLor Sn(Oct)₂ as the catalyst. For the synthesis in the presence ofSn(Oct)₂, the procedure began by putting the D,L-lactide (recrystallizedfrom ethyl acetate before use) in a dry round flask under an argonatmosphere. DEGMEE and Sn(Oct)₂ were added to the flask. Then, thereaction mixture was heated at 150° C. for 24 hrs. After cooling to roomtemperature, the crude product obtained was dissolved in certainquantity of DCM and precipitated from hexanes. The precipitated polymerwas collected by filtration and then redissolved in DCM followed byprecipitation from hexanes once again. Finally, the collected PLA-OH wasdried under vacuum at 40° C. for 48 hrs.

Results

Results show that D,L Lactide was polymerized using both organometalliccoordination-insertion polymerization methods. Table 13 illustrates theselected results obtained from both synthesis methods as well as theresult for the organocatalytic coordination-insertion polymerization inthe presence of DMAP.

TABLE 13 Results obtained from three methods of preparation of PLA-OH.Mn Mass Yield Time/Temperature/ Method (g/mol) (g) (%) Solvent SelectedDMAP 1550 12.9 56 24 h/80° C./NMP Yes DBTDL 1600 14.0 62 72 h/145°C./NMP No Sn(Octc)₂ 1750 27.3 94 24 h/150° C./None Yes

As illustrated, all three syntheses led to a comparable molecular weight(Mn) and those values are inside the expected range value of Mn which isbetween 1500 and 2500. However, the yields obtained from each method arevery different. Table 13 also illustrates that the synthesis in thepresence of DBTDL required 72 hrs to produce a yield of 62% while thesynthesis with Sn(Oct)₂ led to a yield of 94% in 24 hrs. In the case ofthe synthesis in the presence of DMAP, the yield obtained is similar tothe DBTDL method, except in this case only 24 hrs were required. Allthree methods seem very promising but the methods with DMAP and Sn(Oct)₂have been selected for more development and preliminary optimization.The selection was made strictly based on the yield obtained without anyoptimization and the experimental conditions, especially the timerequired to produce the obtained yield.

Synthesis of PVP-PLA

PLA-OH obtained from the DMAP and Sn(Oct)₂ was used to produce PVP-PLA.Both PLA-OHs were converted to a macro chain transfer agent bysubstituting the terminal hydroxyl group by an O-ethyl xanthate group.The substitution of the hydroxyl group required two steps as illustratedin Schemes 12 and 13. After the substitution, the resulting macro chaintransfer agent of PLA was used to polymerize the NVP as indicated inScheme 14.

Preparation of PLA-Br

PLA-OH was dissolved in THF (distilled before use) in a driedround-bottom flask with triethylamine while stirring under argonatmosphere. The reaction mixture was cooled in an ice bath. After thecooling, 2-bromopropionyl bromide was added drop wise from an additionflask. The reaction mixture was then stirred for 72 hrs at roomtemperature. The precipitated trimethylamine salt was removed byfiltration and the filtrate was evaporated until dryness. The solidproduct was dissolved in dichloromethylene (DCM) and washed methodicallywith saturated sodium bicarbonate solution (4×200 mL). The organic layerwas washed with water (4×300 mL), dried over anhydrous sodium sulphate,and filtered. The filtrate was concentrated by evaporation andprecipitated from hexanes and dried under vacuum at 40° C. for 48 hrs.Table 14 and Scheme 12 illustrate, respectively, the quantity ofreactants used and the synthesis route of the preparation of PLA-Br.

TABLE 14 Quantity of each compound used for the preparation of PLA-Br.Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL) PLA-OH 1550 12.500.0081 N/A 2-Bromopropionyl 215.87 4.37 0.0203 2.061 bromideTriethylamine 101.19 2.58 0.0255 0.726 THF 72.11 183.14 2.5397 0.889

Scheme 12 depicts a synthesis route for the preparation of PLA-Br usingthe PLA-OH previously obtained.

Potassium O-Ethyl Xanthate Incorporation to Produce PLA-POEX

The prepared PLA-Br was mixed with potassium ethyl xanthogenate(previously prepared and dried under vacuum at 40° C.) in a driedround-bottom flask, dried DCM was added to disperse the both solids andthe mixture was purged with argon during 2 hrs. In another driedround-bottom flask, pyridine was mixed with DCM while stirring underargon for also 2 hrs. The DCM solution was added to the reaction mixtureof PLA-Br and kept under continuous stirring and argon for 1 h. Then,the reaction mixture was stirred at room temperature for 48 hrs. Thereaction solution was washed consecutively with saturated ammoniumchloride solution (4×200 mL) and saturated sodium bicarbonate solution(4×200 mL). The organic layer was washed with more water (4×200 mL),dried over anhydrous sodium sulphate, and filtered. The filtrate wasconcentrated by evaporation and precipitated from hexanes and driedunder vacuum at 40° C. for 48 hrs. Table 15 and Scheme 13 illustrate,respectively, the quantity of reactants used and the synthesis route ofPLA-POEX.

TABLE 15 Quantity of each compound used for the preparation of PLA-POEX.Mw Mass used Density Compounds (g/mol) (g) Mole (g/mL) PLA-Br 1685 10.000.0059 N/A Potassium O-Ethyl 160.3 4.08 0.0255 2.061 Xanthate Pyridine101.19 2.58 0.0255 0.726 DCM 84.93 185.00 2.1783 1.325

Scheme 13 depicts a synthesis route for the preparation of PLA-POEXusing the PLA-Br obtained previously.

Preparation of PVP-PLA

In a dried round-bottom flask, PLA-POEX (previously dried under vacuumat 40° C.) was dissolved in THF (freshly distilled or freshly openanhydrous bottle). To this solution, NVP and AIBN were added anddissolved. The homogeneous solution was stirred and degassed with argonfor 2 hours. The reaction flask was put in an oil bath preheated at 80°C. for 48 hours. After this time, the crude PVP-PLA was dissolved inDCM, precipitated from hexanes and dried under vacuum at 40° C. forovernight. The polymer was purified more by repeated the dissolution inDCM and precipitated from hexanes a second time, and finally dried undervacuum at 40° C. for 48 hrs. Table 16 and Scheme 14 illustrate,respectively, the quantity of reactants used and the scheme of thesynthesis of PVP-PLA.

TABLE 16 Amount of each raw material used for the preparation of PVP-PLAMw Mass used Density Compounds (g/mol) (g) Mole (g/mL) PLA-POEX 19259.75 0.0051 N/A NVP 111.14 15.34 0.1380 1.040 AIBN 164.21 0.75 0.0046N/A THF 72.11 80.01 1.1096 0.889

Scheme 14 depicts a synthesis route for the preparation of PVP-PLA usingthe PLA-POEX obtained previously.

Characteristics of PVP-PLA Obtained

Four batches of PVP-PLA were prepared, one from PLA-OH with DMAP as thecatalyst and the three others from PLA-OH with Sn(Oct)₂ as the catalyst.All four batches were characterized using multiple of techniques. Thegoal was to confirm the properties according to requirements and also toshow the reproducibility and robustness of the method.

Table 17 illustrates the yield obtained for each synthesis. All threesyntheses with Sn(Oct)₂ led to a much better yield and efficiency thanthe synthesis with DMAP.

TABLE 17 Obtained yield and efficiency for the preparation of PVP-PLAYield (%) Quantity PLA- PLA- PLA- PLA- Effi- Method (g) OH Br POEX PVPciency DMAP 12.0 56 85 80 64 25% Sn(Octc)₂-1 20.5 94 93 80 82 57%Sn(Octc)₂-2 23.8 94 91 81 95 66% Sn(Octc)₂-3 23.6 94 91 81 94 65%

Following the validation of the molecular weight using GPC-LS and protonNMR techniques, thermogravimetric analysis (TGA) as well as elementalanalysis (EA) and proton NMR were applied to determine the PLA contentof each polymer.

Table 18 illustrates the results obtained from each method. As expectedfrom the molecular weight results, the PLA content was be between 35 and45%. The results from the proton NMR and EA techniques again show thereproducibility of the Sn(Oct)₂ method.

TABLE 18 Obtained PLA content value from TGA, EA and proton NMR. PLA %¹Polymers TGA (wt %) EA (wt %) NMR (wt %) WB-DMAP 70 52.5 57 WB-1 54 40.742 WB-2 43 39.4 36 WB-3 44 42.5 37 ¹The average PLA % from the Labopharmmethod is 33% for TGA and 36.3 for EA.

Polymer Properties in Solution

To establish the capacity of each polymer to form micelle, a polymersolution was prepared at a concentration of 90 mg/mL in phosphate buffer100 mM at 25° C. and then the size distribution of each polymer wasmeasured. FIG. 1 shows the size distribution profile obtained for eachpolymer. Once again, the size distribution confirms the reproducibilityof the Sn(Oct)₂ method. However the size distribution observed forWB-DMAP polymer is completely different (more than 2 times smaller).This result is not surprising given that the molecular weight obtainedfor this polymer is 35% lower than the average value for polymers WB-1,WB-2 and WB-3. All four polymers show a unimodal size distribution.Further purification was required to obtain this unimodal distribution.

FIG. 1 depicts micelle size distribution obtained from three differentbatches of the new PVP-PLA polymer.

Table 19 shows the size value and the PDI value measured for all fourpolymers. As shown, polymers from Sn(Oct)₂ method led to equivalentsizes. Critical micelle concentration (CMC) is another physical propertymeasured, and the results obtained for all polymers from Sn(Oct)₂ methodare also equivalent. The results are very different from DMAP method.

TABLE 19 Obtained Particle size and CMC for each polymer. Particle SizeCMC Polymers Size (nm) PDI (mg/mL) WB-DMAP 16 0.085 3.0 WB-1 47 0.2071.8 WB-2 45 0.198 1.6 WB-3 51 0.261 2.0

Here, CMC in 10 mM PBS solution at room temperature was determined frompyrene excitation spectra (lem=390 nm) and expressed as a ratio ofexcitation intensity at 337 and 333 nm.

Synthesis of Additional Polymers

Given the success with the Sn(Oct)₂ method, five additional polymers,WB-4 to WB-8 were prepared using the PLA-OH approach with Sn(Oct)₂ asthe catalyst. Table 20 lists characteristics of polymers produced by thePLA-OH approach. Herein, it should be noted that M_(n) was determined byproton nuclear magnetic resonance (NMR) in deuterated DMSO at roomtemperature, and by from gel permeation chromatographic with lightscattering detector (GPC-LS). Values from GPC-LS were determined inDMF-LiBr (10 mM) at a polymer concentration of 5 mg/mL and using astandard of Polystyrene with M_(n) of 30 k and a PDI of 1.008 tocalibrate the system. The required do/dc value for each polymer wasmeasured and the temperature of the system was fixed at 35° C. Percentvalues under “TGA” were determined from M_(w) values determined bythermogravimetric analysis. Table 20 lists the properties of variouspolymers produced. It should be noted that the PLA:PVP values iscalculated using the PLA-POEX Mn value obtained from Proton NMR, fromwhich the mass of PEOX (121.2) and the initiator alcohol (134.2) havebeen subtracted.

Mn from Proton NMR Method Name PLA-OH PLA-Br PLA-PEOX PVP PVP-PLAPLA-PVP DMAP WB-DMAP 1550 1690 1810 1340 3150 1.16 Sn(Oct)₂ WB-2 17501960 2100 2850 4950 0.65 Sn(Oct)₂ WB-2 1750 2100 2250 4050 6300 0.49Sn(Oct)₂ WB-3 1750 2100 2250 3900 6150 0.51 Sn(Oct)₂ WB-4 2110 2470 27202865 5585 0.86 Sn(Oct)₂ WB-5 1970 2185 2915 3505 6420 0.76 Sn(Oct)₂ WB-61930 2370 2665 3325 5990 0.72 Sn(Oct)₂ WB-7 2030 2195 2365 1960 43251.08 Sn(Oct)₂ WB-8 1880 1965 2745 2055 4800 1.21 Polymers Min Max AveMin Max Ave Min Max Ave Group 1 All 1550 2110 1858 1690 2470 2115 18102915 2424 Group 2 WB1-6 & 8 1750 2110 1877 1950 2470 2164 2100 2925 2521Group 3 WB1-6 1750 2110 1877 1960 2470 2193 2100 2915 2483 Group 4 WB4-61930 2110 2003 2185 2470 2342 2665 2925 2767 Min Max Ave Min Max Ave MinMax Ave Group 1 1340 4050 2872 3150 6420 5297 0.49 1.21 0.83 Group 22055 4050 3221 4800 6420 5742 0.49 1.22 0.74 Group 3 2850 4050 3416 49506420 5899 0.49 0.86 0.67 Group 4 2855 3505 3232 5585 6420 5998 0.72 0.860.78 Average Mn and PDI from unit number GPC-LS² TGA PVP PLA* PVP- % %Name (m) (n) PLA PDI PLA PVP WS-DMAP 12 21 3708 1.11 WB-1 26 22 51921.37 54 46 WB-2 36 22 6283 1.13 43 57 WB-3 35 22 5828 1.32 44 56 WB-4 2627 5693 1.35 43 57 WB-5 32 26 5994 1.64 40.1 59.9 WB-6 30 25 5566 1.2543.8 56.2 WB-7 18 26 6848 1.37 52.7 47.3 WB-8 19 24 6594 1.25 52.7 47.3Polymers Min Max Ave Min Max Ave Min Max Ave All 12 36 26 21 27 24 37086848 5745 WB1-6 & 8 19 36 29 22 27 24 5192 6594 5879 1-6 26 36 31 22 2724 5192 6283 5759 4-6 26 32 29 25 27 26 5566 5994 5751 Polymers Min MaxAve Min Max Ave Min Max Ave All 1.11 1.64 1.31 40 54 47 WB1-6 & 8 1.131.64 1.33 40 54 45 46 60 54 1-6 1.13 1.64 1.34 40 54 45 46 60 55 4-61.25 1.64 1.41 40 44 42 56 60 58

Discussion of Examples 1 & 2

From all syntheses and characterizations performed and presented, thePLA-OH approach is the most promising, being unexpectedly more efficientthan counterpart PVP-OH approaches.

Of the three methods illustrated for the advantageous PLA-OH approach,the Sn(Oct)₂ method gave the highest total yield for the preparation ofPVP-PLA (66% in comparison of 25% for DMAP). This method has also shownvery good reproducibility and robustness. Even without any additionaloptimization, a good control of the molecular weight and PDI with theSn(Oct)₂ method was achieved. For all those reasons, the Sn(Oct)₂ methodand polymers produced using this method were selected for further studyand optimization.

Example 3: Pharmaceutical Formulations Introduction

Control of pain is a significant burden on patients, health services,and society. For example, there are over 100 million surgeries performedin the USA alone each year and 80% of patients experience postoperativepain that is moderate severe necessitating analgesic intervention.

In over 50% of cases, patients receive an opioid drug administeredintravenously to combat the pain. The second most commonly used agentsto treat postoperative pain are non-steroidal anti-inflammatory drugs(NSAIDS) and acetaminophen; these drugs may be used alone to treatmoderate pain and as part of a multimodal approach to supplement andreduce the dose and frequency of concomitant opioid analgesia where theyhave been proven effective. NSAID drugs and acetaminophen however sufferone common drawback in their use as intravenous analgesics: that of poorsolubility coupled in many cases with relatively low potency. Previousattempts to overcome this drawback have been varied.

For instance, the high required dose (up to 4000 mg/day) and lowsolubility of acetaminophen have been circumvented by the development ofproducts such as Ofirmev™ (Mallinckrodt) and Caldolor (CumberlandPharmaceuticals). These are low concentration large volume formulationsthat must be infused slowly to the patient. While such low concentrationsolutions provide benefit the patient must be fitted with a newintravenous line to administer the product (causing inconvenience,discomfort and treatment cost) and the slow infusion results in a lowerCmax and later Tmax for the product than could be achieved if a bolus orslow push intravenous dose was administered. These products must beadministered every 4-6 hours

Elsewhere, Pfizer developed a water soluble pro-drug new chemical entityof their potent COX-2 inhibitor valdecoxib (Bextra™), called Dynastat®(parecoxib), in order to overcome the intrinsic insolubility ofvaldecoxib. The product must be administered every 4-6 hrs. While thisis an excellent post-operative analgesic, the costs and time required todevelop new chemical entities, along with the inherent patient topatient variability that results with pro-drugs does not make this acost-effective option. The time taken for pro-drug hydrolysis andactivation may also delay analgesic onset for the first, most importantadministration.

Products such as Toradol™ (ketorolac for injection) and Dynastat™(diclofenac for injection) use novel formulation approaches to overcomeintrinsic NSAID insolubility. Thus Toradol employs organic solvents (notbeneficial for the patient) in which ketorolac is soluble while Dylojectemploys hydroxypropyl beta-cyclodextrin as a solubilizing agent.Unfortunately, despite these approaches, both Toradol and Dylojectsuffer from instability problems and have been the subject of numerousproduct recalls and market withdrawals; supply shortages are common;again these products must be administered every 4-6 hours.

Pain control drugs of low solubility (including Fluriboprofen,Celecoxib, and Acetaminophen) were selected as examples for formulationwith the block copolymers described herein. In parallel, the hydrophobicnon-opioid anesthetic propofol was selected as further example forformulation.

Methods & Results Flurbiprofen Formulations Flurbiprofen Formulationwith Polymer WB-2

Flurbiprofen (termed “Flu”) formulation was prepared as follows. 12.8 gof the PVP-PLA block copolymer WB-2 and 3.2 g of flurbiprofen weredissolved in 16 mL of ethanol at room temperature for approximately 15minutes to give a final solution having a concentration of 200 mg/mLflurbiprofen and of 800 mg/mL PVP-PLA, respectively. To this solution,16 mL mL of water was added drop-by-drop at the rate of approximately 2mL/min under vigorous stirring using a stirring bar. To this mixture, 13mL of 1N NaOH aqueous solution was added under stirring to bring pH toapproximately 6.9. Next, 260 mL of water was added to the mixture overca. 25 min under vigorous stirring followed by the addition of 12.8 mLof 100 mM sodium phosphate buffer pH 7.0. The mixture was thenmaintained under magnetic stirring over approximately 10 min. Next, thesolution was concentrated to approximately 65% of its initial weightunder reduced pressure in a Büchi Collegiate Rotavapor® equipped with adry ice solvent trap and a Heidolph Rotavac Valve vacuum pump. Thetemperature of water bath was maintained at 30-35° C. The mixture wasthen diluted with water to obtain final flurbiprofen concentration of12.5 mg/mL and filtered through 0.2 um Nylon Target2 filters (ThermoScientific). The resulting solution had an ethanol content ca. 0.2%(wt/wt). The filtered formulation was then transferred into 10 mL glassvials by 4 mL aliquots, corresponding to 50 mg of flurbiprofen. Thevials containing the mixture were freeze-dried using a VirTis Genesis25EL lyophilizer. The composition of the resulting lyophilizedflurbiprofen cakes is shown in Table 21.

TABLE 21 Ingredients mg/vial %/vial Flurbiprofen 50.0 19.2 PVP-PLAcopolymer WB-2 200.0 76.5 Sodium hydroxide 8.3 3.2 Sodium phosphatemonobasic 1.6 0.6 Sodium phosphate dibasic 1.4 0.5 Total 261.3 100%

Accordingly, a drug loading level (DLL) of almost 20% (wt/wt) wasachieved.

X-ray powder diffraction patterns (XRPD) were registered forflurbiprofen API, a physical mixture of flurbiprofen and PVP-PLA blockcopolymer WB-2 containing 20% (w/w) of API, and for the lyophilizedflurbiprofen cake. XRPD measurements for flurbiprofen and the physicalmixture were performed on a Bruker D8 Discover diffractometer, whereasthe diffraction pattern for the lyophilized cake was registered on aBruker D8 Advanced instrument. Both instruments were equipped withcopper Kα1 source of X-rays (λ=1.54 Å) and used Bragg-Brentano Θ-2Θgeometry. FIG. 2 shows the XRPD patterns for flurbiprofen and itsphysical mixture with PVP-PLA. In both cases, the presence ofwell-defined sharp peaks confirms the crystalline nature of the API.

FIG. 3 shows the XRPD pattern of lyophilized flurbiprofen cake thatcontains the same amount of the API as the physical mixture shown inFIG. 2. However, in this case, the sharp peaks of crystallineflurbiprofen were not observed. This confirms that in the freeze-driedsolid formulation of flurbiprofen, the API is present in amorphousstate.

FIG. 4, panel A shows the picture of the freeze-dried cake and thesolution obtained after reconstitution of the cake with water forinjection at a flurbiprofen concentration of 50 mg/mL. The cake shows afine sponge-like structure with no cracking or collapse. Closerinspection of the reconstituted liquid (FIG. 4, panel B) confirms theclarity of solution and the absence of visible solid particles.

Lyophilized cakes were reconstituted in water for injection in less than2 min to give clear, particle-free solutions having a flurbiprofenconcentration of 50 mg/mL. The pH of reconstituted solutions was in therange from 7.2 to 7.4 measured using an Accumet AP61 pH-meter equippedwith a gel-filled epoxy-body combination electrode. Opticaltransmittance was determined in 1-cm disposable polystyrene cuvettes onan Agilent Cary UV-Vis-NIR 5000 spectrometer. The measurements wereperformed at 650 nm and room temperature using empty cuvette as a blank.The reconstituted mixtures had optical transmittance between 99% and102%. Osmolarity of reconstituted samples was measured with a freezingpoint depression 3300 Micro-Osmometer (Advanced Instruments) and it wasin the range of 320 to 340 mOsm/kg. Z-average size of micelles and theirsize distribution was determined at 25° C. by dynamic light scatteringusing a Malvern Zetasizer Nano ZS equipped with 10 mW He—Ne laseroperating at 633 nm. Z-average particle size and its polydispersityvaried from 31.5 to 31.8 nm and from 0.24 to 0.28, respectively.

FIG. 5 shows that the particle size distribution for the flurbiprofenformulation reconstituted at 50 mg/mL is unimodal and that thevolume-average size of micelles varies from ca. 8 to ca. 100 nm.

Stability of the freeze-dried flurbiprofen cakes prepared with thePVP-PLA block copolymer WB-2 was monitored at 25° C./65% RH and 40°C./75% RH. FIG. 6 shows the XRPD pattern of the drug product at timezero and after T=3 months of storage in both conditions. The absence ofwell-resolved sharp peaks of crystalline flurbiprofen confirms that theAPI can preserve its amorphous state at least for 3 months in bothconditions. This data has been extended to T=6 months, wherein theabsence of well-resolved sharp peaks of crystalline Flurbiprofen againconfirmed that the API can preserve its amorphous state at least for 6months at both conditions (data not shown).

The characteristics of reconstituted cakes (flurbiprofen=50 mg/mL) atdifferent stages of stability assessment are shown in Table 22. Nosignificant changes were observed upon 6 months of storage at both 25and 40° C., confirming thus the stability of the freeze-dried product.

TABLE 22 Flurbip- Optical Z- rofen transmit- average assay tance sizeOsmolality (%) pH (%) (nm) (mOsm/kg) T0 98.3 7.33 101.7 31.2 332 T = 1 M99.3 7.32 101.8 35.4 334 (40° C./75% RH) T = 2 M 101.0 7.25 101.6 39.2348 (40° C./75% RH) T = 3 M 98.4 7.13 99.2 40.0 354 (40° C./75% RH) T =6 M 99.7 6.87 100.6 43.6 378 (40° C./75% RH) T = 3 M 100.2 7.44 98.831.1 312 (25° C./65% RH) T = 6 M 101.0 7.39 101.5 31.4 317 (25° C./65%RH)

Flurbiprofen Formulations with Polymers WB-4 and WB-7

Given the success with WB-2, formulations of FLU with WB-4 and WB-7polymers were attempted. WB-4 or WB-7 PVP-PLA block copolymers were eachdissolved together with flurbiprofen in 2.75 mL of ethanol undermagnetic stirring in a glass beaker at room temperature forapproximately 15 minutes to give the solution a concentration of 200 and800 mg/mL of flurbiprofen and PVP-PLA block copolymer, respectively. Toboth these solutions, 2.75 mL of water was added drop-by-drop over ca. 1min. and under vigorous stirring using a magnetic stirring bar andstirring plate. 1N NaOH aqueous solution was added next under stirringto bring pH close to neutral (6.2-6.8). Finally, water was added to themixture under vigorous stirring, followed by the addition of 2.2 mL of100 mM sodium phosphate buffer pH 7.0. The mixtures were then kept undermagnetic stirring over approximately 10 min. Next, both solutions wereconcentrated to approximately 60% of their initial weight under reducedpressure in a Büchi Collegiate Rotavapor® equipped with a dry icesolvent trap and a Heidolph Rotavac Valve vacuum pump. The temperatureof the water bath was maintained at 30-35° C. Resulting transparentsolutions were then diluted with water to obtain a final flurbiprofenconcentration of 12.5 mg/mL, and filtered through 0.2 um Nylon Target2filters (Thermo Scientific). Filtered formulations were transferred as 4mL aliquots (corresponding to 50 mg of Flurbiprofen) into 10 mL glassvials. Filled vials were freeze-dried using a VirTis Genesis 25ELlyophilizer. In Table 23 are shown amounts of products used forpreparation of flurbiprofen formulations with WB-4 or WB-7 polymers. Thecomposition of the resulting lyophilized flurbiprofen cakes preparedusing WB-4 or WB-7 polymers are shown in Table 24 and Table 25,respectively.

Lyophilized cakes were reconstituted in water for injection in less than1 min to give clear, particle-free solutions having flurbiprofenconcentration of 50 mg/mL. pH of reconstituted solutions for theformulations obtained with both polymers was in the range from 7.2 to7.4 as measured using an Accumet AP61 pH-meter equipped with agel-filled epoxy-body combination electrode. Osmolality of reconstitutedsamples was measured with a freezing point depression 3300Micro-Osmometer (Advanced Instruments) and it was in the range of 380 to420 mOsm/kg. Optical transmittance was determined in 1-cm disposablepolystyrene cuvettes using an Agilent Cary UV-Vis-NIR 5000 spectrometer.The measurements were performed at 650 nm and room temperature usingempty cuvette as a blank. The reconstituted solutions prepared form thecakes containing WB-4 polymer showed optical transmittance between 98%and 100%. The solutions of the samples prepared using polymer WB-7 haveslightly lower transmittance, in the range 84-85%. Z-average size ofmicelles and their size distribution was determined at 25° C. by dynamiclight scattering using a Malvern Zetasizer Nano ZS equipped with 10 mWHe—Ne laser operating at 633 nm. Z-average particle size for bothreconstituted formulations of the cakes containing WB-4 and WB-7 wassimilar and equal to 43.9 and 43.6 nm, respectively. FIG. 7 shows thatparticle size distributions for formulations prepared using twodifferent polymer samples WB-4 and WB-7 and reconstituted at 50 mg/mLhave similar shape with the volume-average size of micelles from ca. 10to ca. 200 nm. Values of the parameters determined upon characterizationof reconstituted Flurbiprofen formulations are shown in Table 26.

TABLE 23 WB-4 WB-7 PVP-PLA copolymer (WB-4 or WB-7), mg 2200 2200Flurbiprofen, mg 550 550 Ethanol, mL 2.75 2.75 Water (beforeevaporation), mL 44.50 45.50 Sodium hydroxide solution (1N), mL 3.402.40 Sodium phosphate buffer (100 mM, pH 7.0), mL 2.20 2.20 Ratio offormulation weight after and before 0.63 0.59 evaporation Water addedafter evaporation to adjust FLU 10.00 12.70 concentration to 12.5 mg/mL

TABLE 24 Ingredients mg/vial %/vial Flurbiprofen 50.0 17.2 PVP-PLAcopolymer WB-4 200.0 68.7 Sodium hydroxide 12.3 4.2 Sodium phosphatemonobasic 120 13.2 4.5 Sodium phosphate dibasic 142 15.6 5.4 Total 291.1mg 100%

TABLE 25 Ingredients mg/vial %/vial Flurbiprofen 50.0 17.3 PVP-PLAcopolymer WB-7 200.0 69.4 Sodium hydroxide 9.6 3.3 Sodium phosphatemonobasic 13.2 4.6 Sodium phosphate dibasic 15.6 5.4 Total 288.4 mg 100%

TABLE 26 Parameter WB-4 WB-7 Reconstitution time (s) 30 50 pH 7.29 7.22Osmolality (mOsm/kg) 419 380 Optical transmittance (%) 99.1 84.2Z-average particle size (nm) 43.9 43.6 Particle size distribution 0.2730.233

Flurbiprofen Formulations with Other PLA-OH Polymers

Given the above successes, the ability of other polymers derived fromthe PLA-OH method were tested for their ability to formulate FLU, i.e.,polymers WB-DMAP, WB-1, WB-3, WB-5, WB-6, and WB-8. All polymers werefound to be capable of formulating FLU, achieving a suitably clearsolutions having a suitable DLL.

Acetaminophen Formulations Acetaminophen Formulation with Polymer WB-2(no antioxidant)

Acetaminophen (APAP) formulation was prepared as follows. 4.40 g of APAPwas dissolved in 29 mL of ethanol in a glass beaker under stirring atroom temperature for approximately 10 minutes following the addition of20.05 g WB-4 block copolymer and an additional 10 minutes stirring. Tothis solution, 200 mL mL of water was added drop-by-drop at the rate ofapproximately 10 mL/min and under vigorous stirring using a stirringbar. To this mixture, 0.38 mL of 1N NaOH aqueous solution was addedunder stirring to bring the pH to approximately 7.1. Next, 200 mL ofwater was added to the mixture over ca. 20 min under vigorous stirringfollowing by the addition of 12.2 mL of aqueous solution of mannitol atconcentration 100 mg/mL. Stirring continued for an additional 10 min.Next, the solution was concentrated during ca. 2 hrs to 42% of itsinitial weight under reduced pressure in a Büchi Collegiate Rotavapor®equipped with a dry ice solvent trap and a Heidolph Rotavac Valve vacuumpump. The temperature of the water bath was maintained at 30-35° C. Tothe concentrated solution, 4.9 mL of 100 mM sodium phosphate buffer pH7.0 was added. The mixture was then diluted with 29 mL of water toobtain final APAP concentration of 20 mg/mL and filtered through 0.2 umNylon Target2 filters (Thermo Scientific). Filtered formulation was thentransferred into 10 mL glass vials by 5 mL aliquots, corresponding to100 mg of APAP. The vials containing the formulation were freeze-driedusing a VirTis Genesis 25EL lyophilizer. The composition of theresulting lyophilized acetaminophen cakes is shown in Table 27.

TABLE 27 Ingredients mg/vial %/vial Acetaminophen 100.0 17.09%  PVP-PLAcopolymer WB-4 455.6 77.88%  Mannitol 27.8 4.75% Sodium hydroxide 0.20.03% Sodium phosphate monobasic 0.6 0.11% Sodium phosphate dibasic 0.80.13% Total  100%

According, a DLL of over 17% was achieved.

X-ray powder diffraction patterns (XRPD) were registered foracetaminophen API and for the lyophilized acetaminophen cake. XRPDmeasurements were registered on a Bruker D8 Advanced instrument equippedwith copper Kα₁ source of X-rays (λ=1.54 Å) and used Bragg-Brentano Θ-2Θgeometry. FIG. 8 shows the XRPD patterns for acetaminophen API andlyophilized cake of drug product. The presence of sharp peakscharacteristic for crystalline acetaminophen was not detected, in thecase of APAP formulation, not observed, confirming that in thefreeze-dried solid cakes the API is present in amorphous state.

FIG. 9 shows the picture of the freeze-dried cake and the solutionobtained after reconstitution of the cake with water for injection atthe acetaminophen concentration of 50 mg/mL. The cake show finesponge-like structure with no cracking or collapse. Close inspection ofthe reconstituted liquid (FIG. 9b ) confirms the clarity of solution andthe absence of visible solid particles.

Lyophilized cakes undergo complete dissolution in water in ca. 2-3 minto give clear, particle-free solutions having acetaminophenconcentration of 50 mg/mL. pH of reconstituted solutions was in therange from 7.5 to 7.7 as measured using an Accumet AP61 pH-meterequipped with a gel-filled epoxy-body combination electrode. Opticaltransmittance was determined in 1-cm disposable polystyrene cuvettes onan Agilent Cary UV-Vis-NIR 5000 spectrometer. The measurements wereperformed at 650 nm and room temperature using empty cuvette as a blank.The reconstituted mixtures had an optical transmittance of around 86%.Osmolality of reconstituted samples was measured with a freezing pointdepression 3300 Micro-Osmometer (Advanced Instruments) and it was in therange of 250 to 265 mOsm/kg. Z-average size of micelles and their sizedistribution was determined at 25° C. by dynamic light scattering usinga Malvern Zetasizer Nano ZS equipped with 10 mW He—Ne laser operating at633 nm. Z-average particle size and its polydispersity varied from 48 to51 nm and from 0.19 to 0.22, respectively. FIG. 10 shows that particlesize distribution for APAP formulation reconstituted at 50 mg/mL ismonomodal and that the volume-average size of micelles varies from ca.15 to ca. 200 nm.

Acetaminophen Formulations with Polymers WB-4 and WB-7

Given the above success, APAP formulations with WB-4 and WB-7 polymerswere prepared as follows. APAP was dissolved in 3 mL of ethanol in aglass beaker under stirring at room temperature for approximately 5minutes following addition of WB-4 or WB-7 block copolymer and anadditional 10 minutes stirring. To these solutions, 40 mL of water wasadded drop-by-drop at the rate of approximately 10 mL/min. and undervigorous stirring. Next, 0.1N NaOH aqueous solution was added to bringpH to approximately 7.2 following by the addition of 40 mL of water overca. 10 min. In the next step, 1.25 mL of aqueous solution of mannitol atconcentration 100 mg/mL was added to both solutions and the stirringcontinued for the additional 10 min. Both formulations were subsequentlyconcentrated for ca. 30-40 min. to 20-40% of its initial weight underreduced pressure in a Büchi Collegiate Rotavapor® equipped with a dryice solvent trap and a Heidolph Rotavac Valve vacuum pump. Temperatureof the water bath was maintained at 40-45° C. To each of theseconcentrated solutions, 0.5 mL of 100 mM sodium phosphate buffer pH 7.0was added. The mixtures were then diluted with water to obtain finalAPAP concentration of 20 mg/mL. The solutions were filtered through 0.2um Nylon Target2 filters (Thermo Scientific). Filtered formulations werethen transferred into 10 mL glass lyophilisation vials in 5 mL aliquots,corresponding to 100 mg of APAP. The vials containing the formulationswere freeze-dried using a VirTis Genesis 25EL lyophilizer. In Table 28are listed the products used to prepare solid reconstitutedacetaminophen formulations containing WB-4 or WB-7 polymers. Thecompositions of the resulting lyophilized cakes are shown in Tables 29and 30, respectively.

Lyophilized cakes of formulation prepared using polymer WB-4 werereconstituted in water for injection in less than 3 minutes to giveclear, particle-free solutions of acetaminophen concentration 50 mg/mL.In contrast, the reconstitution of the cakes prepared with WB-7 polymerwas much faster (less than 1 min.), but the resulting solutions showedsignificant cloudiness in this case. This difference is furthersupported by optical transmittance measurements. The reconstitutedformulations containing WB-4 polymer are characterized by opticaltransmittance of ca. 95%. The solutions of the formulations preparedusing polymer WB-7 have significantly lower transmittance, in the range40-42%. While Z-average particle size for reconstituted formulations ofthe cakes APAP/WB-4 was 44.3 nm, the size of the particles in thereconstituted formulation of APAP/WB-7 was much higher and equal to 218nm. FIG. 11 shows that particle size distributions for formulationsprepared using two different polymers WB-4 and WB-7 and reconstituted at50 mg/mL have different shapes with the volume-average size of micellesfrom ca. 10 to ca. 200 nm. This is in strong contrast with the behaviorof flurbiprofen formulations prepared with these two polymers. pH ofreconstituted solutions for the formulations obtained with both polymerswas similar and in the range 7.20-7.25. Osmolality of the reconstitutedsamples was also similar for both polymers and comprised in the range271-281 mOsm/kg. Values of the parameters determined uponcharacterization of reconstituted APAP formulations are shown in Table31.

TABLE 28 WB-4 WB-7 PVP-PLA copolymer (WB-4 or WB-7), mg 2550 2550Acetaminophen, mg 450 450 Ethanol, mL 3.00 3.00 Water (added beforeevaporation), mL 40.00 40.00 0.1N NaOH solution, mL 0.43 0.36 Mannitol(solution of 100 mg/mL), mL 1.25 1.25 Ratio of formulation weight afterand before 0.20 0.37 evaporation Water added after evaporation to adjust12.9 4.9 final APAP concentration to 20 mg/mL, mL Sodium phosphatebuffer (100 mM, pH 0.50 0.50 7.0), mL

TABLE 29 Ingredients mg/vial %/vial Acetaminophen 100.0 14.4 PVP-PLAcopolymer WB-4 566.7 81.4 Mannitol 27.8 4.0 Sodium hydroxide 0.4 >0.1Sodium phosphate monobasic 0.6 >0.1 Sodium phosphate dibasic 0.8 0.1Total 696.3 mg 100%

TABLE 30 Ingredients mg/vial %/vial Acetaminophen 100.0 14.4 PVP-PLAcopolymer WB-7 566.7 81.4 Mannitol 27.8 4.0 Sodium hydroxide 0.3 >0.1Sodium phosphate monobasic 0.6 >0.1 Sodium phosphate dibasic 0.8 0.1Total 696.2 mg 100%

TABLE 31 Parameter WB-4 WB-7 Reconstitution time (s) 150 55 pH 7.20 7.25Osmolality (mOsm/kg) 271 281 Optical transmittance (%) 95.2 41.7Z-average particle size (nm) 44.3 218 Particle size distribution 0.2520.393

Accordingly, DLLs of almost 15% were achieved.

WB-7 was not able to formulate APAP in manner suitable foradministration due to the presence of visible and sub-visible particles.

With WB-4, the resulting solution was deemed to possess propertiessuitable for administration. Further experiments indicated that WB-4could formulate APAP at a DLL of 18% (90% optical transmittance), 20%(84% optical transmittance), and 25% (78% optical transmittance).

Acetaminophen Formulations with Other Polymers

Given the above success with WB-4, other APAP test formulations wereattempted based on the above protocols with polymers WB-5, WB-6, andWB-8 (data not shown). In summary, polymers WB-5, and WB-6 were deemedcapable of making nanodispersions of APAP that were suitable to meetrequirements for administration.

Celecoxib Formulations Celecoxib Formulations with Polymer WB-4

Celecoxib (CEL) formulation was prepared as follows. 450 mg of WB-4block copolymer was dissolved in 1 mL of water for injection undermagnetic stirring during ca. 10 minutes. To the polymer solution, 0.4 mLof 0.1N NaOH aqueous solution was added under stirring to bring the pHto approximately 7.5. Next, 0.25 mL of 100 mM sodium phosphate buffer pH7.0 was added to the solution followed by the addition of 1.25 mL ofaqueous solution of mannitol at concentration 100 mg/mL. Next, 50 mg ofcelecoxib was dissolved in 1 mL of ethanol in glass vial under magneticstirring at room temperature and added drop by drop to polymer solutionduring ca. 1 min. Resulting clear solution was cooled down in the icebath and placed in a cold chamber at 6° C. under stirring for ca. 20min. After removing the sample from a cold chamber, 1.10 mL of water wasadded to the formulation. Next, the solution was concentrated during ca.30 min. to 25% of its initial weight under reduced pressure in a BüchiCollegiate Rotavapor® equipped with a dry ice solvent trap and aHeidolph Rotavac Valve vacuum pump. The temperature of the water bathwas maintained at 30-35° C. To the concentrated solution, 3.64 mL ofwater was added to obtain the formulation of final CEL concentration 10mg/mL. The formulation was then filtered through 0.2 um Nylon Target2filters (Thermo Scientific). Filtered formulation was transferred into10 mL glass vial and freeze-dried using a VirTis Genesis 25ELlyophilizer. The composition of the resulting lyophilized celecoxibcakes is shown in Table 32.

TABLE 32 Ingredients mg/vial %/vial Celecoxib 50.0 7.8% PVP-PLAcopolymer WB-4 450.0 70.0%  Mannitol 125 19.4%  Sodium hydroxide 1.60.2% Sodium phosphate monobasic 7.5 1.2% Sodium phosphate dibasic 8.91.4% Total 643 100% 

Accordingly, a DLL of almost 8% was achieved.

FIG. 12 shows a picture of the freeze-dried cake and the solutionobtained after reconstitution of the cake with water for injection atthe CEL concentration of 25 mg/mL. The cake shows fine sponge-likestructure with no cracking or collapse. Close inspection of thereconstituted liquid (FIG. 12b ) confirms the clarity of solution andthe absence of visible solid particles.

Lyophilized cakes undergo dissolution in water in less than 1 min togive clear, particle-free solutions having celecoxib concentration of 25mg/mL. pH of the reconstituted solutions was in the range from 6.8 to7.2 as measured using an Accumet AP61 pH-meter equipped with agel-filled epoxy-body combination electrode. Optical transmittance wasdetermined in 1-cm disposable polystyrene cuvettes on an Agilent CaryUV-Vis-NIR 5000 spectrometer. The measurements were performed at 650 nmand room temperature using empty cuvette as a blank. The reconstitutedmixtures had optical transmittance of around 92%. Osmolality ofreconstituted samples was measured with a freezing point depression 3300Micro-Osmometer (Advanced Instruments) and it was in the range of 420 to450 mOsm/kg. Z-average size of micelles and their size distribution wasdetermined at 25° C. by dynamic light scattering using a MalvernZetasizer Nano ZS equipped with 10 mW He—Ne laser operating at 633 nm.Z-average particle size and its polydispersity varied from 47 to 52 nmand from 0.38 to 0.45, respectively. FIG. 13 shows that particle sizedistribution for celecoxib formulation reconstituted at 25 mg/mL ismonomodal and that the volume-average size of micelles varies from ca.10 to ca. 200 nm.

Celecoxib Formulations with Other Polymers

Given the above success with WB-4, other CEL test formulations wereattempted with polymers WB-5 to WB-8 based on the above protocols (datanot shown). In summary, polymers WB-5, WB-6, and WB-8 were deemedcapable of making nanodispersions of CEL that were suitable to meetrequirements for administration.

Propofol Formulations

Propofol (PPF) formulations were prepared as follows. 900 mg of PVP-PLApolymer (WB-4, WB-5, WB-6, WB-7, and WB-8) was dissolved in 7.5 mL of100 mM phosphate buffer pH 7.0 in a glass vial under stirring at roomtemperature for approximately 10 minutes following the addition of 100mg (107 uL) of PPF. Solutions were kept under vigorous stirring at roomtemperature for approx. 16 h followed by addition of 2.5 mL of water.FIG. 1 shows the pictures of the formulations before filtration. Sizedistribution of the particles obtained before filtration is shown inFIG. 2. Formulations prepared using polymers WB-4, WB-5, and WB-6 arehomogenous and transparent solutions. They show monomodal particle sizedistribution with the Z-average size of 33 to 44 nm. These formulationswere subsequently filtered through 0.2 um Nylon Target2 filters (ThermoScientific), transferred into 5 mL glass vials by 2 mL aliquots andfreeze-dried using a VirTis Genesis 25EL lyophilizer. In contrast,samples prepared using polymers WB-7 and WB-8 polymers show bimodal sizedistribution and z-average size of ca. 120 nm, they cannot be filteredusing 0.2 um filters and were not analyzed any further.

FIG. 14 depicts a photograph of formulations of PPF prepared with WB-4to WB-8 polymer samples before filtration and freeze-drying, with WB-4to WB-6 producing relatively clear solutions.

FIG. 15 depicts volume-average size distribution of particles informulations of PPF and polymers WB-4 to WB-8 before filtration andfreeze-drying.

Freeze-dried cakes (20 mg of PPF) were reconstituted with 2 water inless than 1 min. upon gentle shaking to give clear, particle-freesolutions having PPF concentration of 10 mg/mL. Table 2 showsphysicochemical properties of reconstituted formulations. pH ofreconstituted solutions was 7.02-7.03 as measured using an Accumet AP61pH-meter equipped with a gel-filled epoxy-body combination electrode.Optical transmittance was determined in 1-cm disposable polystyrenecuvettes on an Agilent Cary UV-Vis-NIR 5000 spectrometer. Themeasurements were performed at 650 nm and room temperature using emptycuvette as a blank. The reconstituted mixtures had optical transmittancebetween ca. 77 and 83%. Osmolality of reconstituted samples was measuredwith a freezing point depression 3300 Micro-Osmometer (AdvancedInstruments) and it was in the range of 188 to 223 mOsm/kg. Z-averagesize of micelles and their size distribution was determined at 25° C. bydynamic light scattering using a Malvern Zetasizer Nano ZS equipped with10 mW He—Ne laser operating at 633 nm. Z-average particle size variedfrom 43.5 to 58.7 nm.

FIG. 16 shows that particle size distribution for PPF formulationsprepared using polymers WB-4, WB-5, and WB-6 is monomodal and that thevolume-average size of micelles varies from ca. 15 to 150 nm.

Table 33 depicts physicochemical characterization of PPF formulationsprepared with WB-4, WB-5, and WB-6 polymer samples and reconstituted at10 mg/mL.

TABLE 33 Polymer batch used in formulation WB-4 WB-5 WB-6 Z-average size(nm) 52.2 58.7 43.5 pH 7.02 7.03 7.03 Optical transmittance (% T) 77.083.1 83.0 Osmolality (mOsm/kg) 201 223 188

All three formulations were suitable for administration.

Summary

Table 34 briefly summarizes formulation results, indicating whichpolymers successfully formulated (Y) which APIs, and which did not (N).

TABLE 34 FLU APAP CEL PPF WB-DMAP Y WB-1 Y WB-2 Y WB-3 Y WB-4 Y Y Y YWB-5 Y Y Y Y WB-6 Y Y Y Y WB-7 Y N N WB-8 Y N Y

Discussion

PVP-PLA block copolymers described herein have been used to increase thewater solubility of a range of drug molecules many thousand fold, and toproduce solid products that reconstitute rapidly in aqueous solution togenerate very high concentration, low viscosity liquids. Further theseformulations have been lyophilized to optimize their stability at bothroom temperature and elevated temperatures as could occur from time totime. These copolymers are able to achieve DLL and concentrations insolution that are suitable for delivery.

The polymers can be classified in terms of their ability to formulateAPIs as follows.

Group 1 polymers have been show to effectively formulate at least oneAPI, i.e. FLU as a micellar composition suitable for delivery to asubject. These include WB-1 to WB-8. WB-DMAP may also be included inthis group.

Group 2 polymers have been show to effectively formulate at least twoAPIs, i.e. FLU and CEL. WB-4 to WB-6 and WB-8 are included in thisgroup. WB-1 to WB-3 were not tested, but should are included due tosimilar properties.

Group 3 polymers have been shown to effectively formulate at least threeAPIs. In fact, they also formulate all four that were tested, i.e. FLU,CEL, APAP, and PPF. WB-4 TO WB-6 are included in this group. Again, WB-1to WB- are also included due to similar properties.

Group 4 polymer may be thought of as a subset of Group 3 that has beensubject to the most rigorous testing, and includes WB-4 TO WB-6.

These groups are listed in Table 20, wherein minimum, maximum, andaverage values for various parameters have been listed for the groups.Trends are apparent in this data, with narrowed ranges or differentaverage values across Groups 1 through 4 being indicative of unexpectedincreases in flexibility. Design parameters could be readily selectedfrom within these ranges to generate polymers having desiredcharacteristics. Selection of target variables for block-copolymers willdepend on requirements, e.g. if it is desired to select a blockco-polymer based on ability to solubilize a specific API, or whether aflexible drug-delivery platform is preferred.

Example 4: Pharmacokinetic Study Introduction

The present study examined the pharmacokinetics (PK) of flurbiprofen(FLU) formulated using SmartCelle micellar nanotechnology (PPI-1501)after intravenous (IV) delivery to rats as described in JRF Report:Single Dose Pharmacokinetic study of Flurbiprofen Formulation throughIntravenous Route in Wistar Rats; JRF International—September 2016. FLUpharmacokinetics as presented in the report were fitted using bothnon-compartmental and two compartment models to assess goodness of fit.

The fitted results obtained in the JRF study were then compared to thosein the literature, generated after administering a non-micellar lowconcentration simple FLU solution IV to rats. This was undertaken todetermine potential differences in FLU pharmacokinetics induced by themicellar formulation.

Both sets of rodent data were then extrapolated using published humanFLU PK parameters to estimate the PK of FLU post IV administration ofPPI 1501 or non-formulated FLU to humans.

Finally the predicted FLU pharmacokinetics following PPI-1501administration to humans were compared to those generated by the IVadministration of the FLU pro-drug flurbiprofen axetil (FA) to humans.The impact of the micellar formulation on FLU pharmacodynamics comparedto a simple solution or the pro-drug were then assessed.

Methods

As per the JRF protocol, Wistar rats were dosed with reconstituted PPI1501 by intravenous injection over 15 seconds via the jugular vein at 3doses these being; 2.5 mg/kg, 10 mg/kg and 30 mg/kg. These doses wereselected to produce exposures in rats encompassing potential humantherapeutic doses, taking into account the differences in clearance ratebetween rats and humans.

Blood samples were collected from 3 rats at the following time points:2, 15, 30, mins, and 1, 2, 4, 6, 12, and 24 hours. Each rat was sampled2 times from the jugular vein.

Results

Variability

The time-concentration profiles of FLU generated by the PPI 1501formulation are summarized in Tables 35-37 and FIG. 17.

TABLE 35 Time concentration profile of FLU in the rats following an IVdose of 2.5 mg/kg PPI-1501 Time (h) Mean SD CV % 0.033 32711.7 5254.816.1 0.25 24044.5 4245.6 17.7 0.50 16917.7 3666.3 21.7 1 15327.0 126.90.8 2 10691.6 452.0 4.2 4 6349.6 1002.5 15.8 6 4823.7 580.8 12.0 121422.0 292.3 20.6 24 308.4 26.1 8.5

TABLE 36 Time concentration profile of FLU in the rats following an IVdose of 10 mg/kg PPI-1501. Time (h) Mean SD CV % 0.033 116699.1 3811.83.3 0.25 66360.2 20807.0 31.4 0.5 64874.4 6517.0 10.0 1 49676.0 5011.710.1 2 39275.7 2915.4 7.4 4 23363.5 2819.5 12.1 6 14256.6 4141.6 29.1 123710.3 688.9 18.6 24 723.7 667.9 92.3

TABLE 37 Time concentration profile of FLU in the rats following an IVdose of 30 mg/kg PPI-1501. Time (h) Mean SD CV % 0.033 250167.4 39639.215.8 0.25 188737.7 6123.3 3.2 0.5 156477.7 7084.9 4.5 1 109774.2 12488.711.4 2 79479.2 4120.6 5.2 4 49066.4 1650.1 3.4 6 37523.6 3727.7 9.9 1211361.0 2090.2 18.4 24 1350.8 595.5 44.1

FIG. 17 itself depicts time concentration profiles of FLU fin ratsfollowing an IV dose of 2.5 (lower line), 10 (middle line) or 30 mg/kg(upper line) PPI-1501.

The inter-animal variability (CV) for most time-points were within 20%.Greater degrees of variation were only seen at later time points whenlevels of FLU were closer to the levels of quantitation of thebio-assay.

Linearity

The data were first analysed using a standard non-compartmental model,results being summarized in Table 38.

TABLE 38 IV PK parameters of FLU from PP11501 based on standardnon-compartmental analysis (NCA) Parameter 2.5 mg/kg 10 mg/kg 30 mg/kgt½ (h) 4.55 4.05 3.81 Cmax (ng/ml) 32712 116699 250167 C₀ (ng/ml) 34298127287 261251 AUC_(t) (ng/ml*h) 90790 294180 698474 AUCi_(nf) (ng/ml*h)92814 298404 705906 MRT (h) 5 4 5 Vz (ml/kg) 177 196 234 CL (ml/h/kg) 2734 42 Vss (ml/kg) 138 150 198 C₀/Dose 13719 12729 8708 AUC 0-t/D 3631629418 23282 AUC 0-inf/D_obs 37126 29840 23530

The dose-normalized plasma concentrations at time 0 (C₀) and AUC_(inf)at the 10 mg/kg dose were 93% and 80% respectively of those observed at2.5 mg/kg while values for these parameters for the 30 mg/kg dose wereboth only 63% of those seen at the 2.5 mg/kg dose. These data suggestacceptable dose linearity at doses between 10 mg/kg and 2.5 mg/kg but areduction in exposure with increasing dose.

For this reason comparisons with rodent intravenous solution data andextrapolations to potential human results shown later in this reportwere performed with the 2.5 mg/kg rat data only. As the predicted humandose of PPI-1501 is 100 mg BID (see below) 2.5 mg/kg represents theupper range of the potential treatment regimen (175 mg for a 70 kgindividual).

The results from the JRF study were then compared to literature valuesfor FLU PK administered as an IV solution as generated by Park and Kim(1) and Knihinicki et al (2); the comparison is shown in Table 39.

TABLE 39 Differences of NCA PK parameters between FLU in PPI 1501 versussolutions at an IV dose of 2.5 mg/kg Ratio PPI- Ratio PPI- Park & PPIPark & 1501 to Park Knihinicki 1501 to Kim/ Parameter 1501 Kim & Kim etal Knihinicki Knihinicki t_(1/2) (h) 4.55 2.78 1.64 3.07 1.48 0.91 MRT(h) 5.11 3.40 1.50 4.07 1.26 0.83 CL (ml/min/kg) 26.94 47.94 0.56 540.50 0.88 Vss (ml/kg) 137.76 156.78 0.88 220 0.63 0.72 AUC_(inf) 9281454080 1.72 46296 2.00 1.17 (ng/ml*h) Vz (ml/kg) 177 192.31 0.92 239 0.740.8

As may be seen, rodent PK results obtained separately for a simple lowdose FLU solution by Park and Kim or Knihinicki were similar for allparameters measured (differences 0.72 to 1.17) indicating that aninter-study meta-analysis, while not providing absolute comparativedata, is acceptable for identifying significant differences betweenadministration of FLU in micellar and non-micellar forms. Parameterswhere considerable differences occurs between simple solution andmicellar delivery are highlighted

Thus, when comparing simple solution values with those obtained with themicellar formulation a number of differences are evident;

1. The half-life (t1/2) of FLU delivered by PPI-1501 is considerablegreater than when administered as a solution.

2. The mean residence time (MRT) of FLU delivered by PPI-1501 is greaterthan when administered as a solution.

3. The clearance rate (CL) of FLU delivered by PPI-1501 is considerableslower than when administered as solution.

4. Most importantly the exposure of the rats to FLU (AUCinf) is veryconsiderably greater when FLU is administered in a micellar form.

FIG. 18 depicts a comparative plasma time-concentration profiles of FLUfollowing the IV dosing of a 2.5 mg/kg FLU solution (redrawn fromReference 1; bottom line) and following IV dosing of PPI-1501 at 2.5mg/kg (top line). Results across the test period highlight the morerapid clearance of FLU when administered as a solution and also thelower Cmax achieved when FLU is administered in micellar form. Note themore rapid initial clearance/redistribution of FLU when administered asa simple solution. In conclusion, administration in micellar formappears to increase the exposure of the rats to FLU.

Analysis using a Two Compartment Model

While NCA was employed earlier to allow comparison of rodent datagenerated using PPI-1501 to literature simple solution data, more recentreports indicate that FLU in both the clinic and in rodents is betterfitted using a 2 compartmental model (2-8). FIGS. 18-20 thereforepresent the JRF data fitted using a 2 compartmental model.

FIG. 19 depicts two compartmental model fitting of the plasmaconcentration profile of FLU dosed as PPI 1501 at the IV dose of 2.5mg/kg.

FIG. 20 depicts two compartmental model fitting of the plasmaconcentration profile of FLU dosed as PPI 1501 at the IV dose of 10mg/kg.

FIG. 21 depicts two compartmental model fitting of the plasmaconcentration profile of FLU dosed as PPI 1501 at the IV dose of 30mg/kg.

Table 40 shows the PK parameters that are generated.

TABLE 40 Two compartmental PK data analysis based on data in Table 21Parameter Unit 2.5 mg/kg 10 mg/kg 30 mg/kg A ng/ml 18256.1 64288.1149620.5 Alpha 1/h 1.26 0.37 1.90 B ng/ml 11044.7 13348.7 105955.4 Beta1/h 0.15 0.12 0.18 k₁₀ 1/h 0.34 0.28 0.39 k₁₂ 1/h 0.51 0.05 0.80 k₂₁ 1/h0.57 0.17 0.90 t_(1/2) Alpha h 0.55 1.86 0.36 t_(1/2) Beta h 4.50 5.673.80 C0 ng/ml 29300.8 77636.9 255575.9 V (ml/kg) 85.3 128.8 117.4 CL(ml/kg/h) 29.0 35.5 45.5 V2 (ml/kg) 75.3 42.1 105.1 CL2 (ml/kg/h) 43.17.0 94.1 AUC 0-t ng/ml*h 84305.2 276029.5 652178.0 AUC 0-inf ng/ml*h86075.0 281876.3 659466.1 MRT h 5.5 4.8 4.9 Vss (ml/kg) 160.6 170.9222.5

For comparative purposes, the rat PK data for a FLU solution generatedby Park and Kim (1) were also fitted to the 2 compartmental model (FIG.22 and Table 41).

FIG. 22 depicts two compartmental model fitting of the plasmaconcentration of FLU dosed as a simple solution at the IV dose of 2.5mg/kg. Note the more pronounced and rapid initial redistribution phaseof the FLU solution compared to FLU from PPI-1501.

Comparison of the IV profile between FLU in PPI 1501 vs FLU in solutionrevealed a lower initial concentration and a slower alpha distributionphase, for the micellar product, mostly likely due to retarded releaseof FLU from the PPI 1501 micelles compared to the simple solution. Incontrast, the elimination constant for FLU formulated as PPI-1501 in thebeta phase was slower than that when FLU was administered as a solution.These values in turn led to the higher V (by 70%) but lower V2 (by 39%)for FLU from PPI 1501 and the 40% and 92% lower CL and CL2 for themicellar formulation.

TABLE 41 Estimated 2 compartmental PK parameters of FLU in solution (2.5mg/kg) and differences of parameter values between FLU in PPI 1501 (2.5mg/kg) Parameter Unit PPI 1501 Reported Solution Ratio A ng/ml 18256.1438065.32 0.48 Alpha 1/h 1.26 7.53 0.17 B ng/ml 11044.66 11751.39 0.94Beta 1/h 0.15 0.25 0.61 k10 1/h 0.34 0.97 0.35 k12 1/h 0.51 4.84 0.10k21 1/h 0.57 1.97 0.29 t½Alpha h 0.55 0.09 5.96 t½Beta h 4.50 2.73 1.64C0 ng/ml 29300.80 49816.71 0.59 V (ml/kg) 85.32 50.18 1.70 CL (ml/kg/h)29.04 48.62 0.60 V2 (ml/kg) 75.29 123.42 0.61 CL2 (ml/kg/h) 43.10 243.110.18 AUC 0-t ng/ml*h 84305.19 45317.51 1.86 AUC 0-inf ng/ml*h 86074.9951421.86 1.67 MRT h 5.53 3.57 1.55 Vss (ml/kg) 160.61 173.60 0.93

Parameters in shaded boxes cells are the most critical for influencingthe time-concentration profile of FIG. 22. Findings are similar to thosewhen non-compartmental analysis was used.

Extrapolations to Human PK and PD Performance

Assuming the plasma PK profile of FLU mediated by IV PPI 1501 in the ratis translatable to human, i.e. that the same PK parameter differenceratios for FLU in PPI 1501 observed in the rat apply in humans, then thehuman IV PK parameters for FLU in PPI 1501 can be estimated. This may beachieved by simple multiplication of the difference ratios provided inTable 41 (last column) to again obtain the comparative human PKparameter values FLU in PPI 1501 versus those obtained from injection ofthe simple solution; such data may also be compared to data obtained byinjecting humans with the prodrug FA (Table 42).

The human IV PK parameters of FLU in solution were estimated based onthe oral PK parameters of FLU and its estimated oral bioavailability(project 1 report, Duan, 2015, Table 42, ref 3-8). From Table 10, it isclear that the estimated MRT following the IV dose of FLU in PPI 1501is >2-fold of FLU in solution and IV dosed FA (Table 42), attributableto the increased V and decreased CL.

TABLE 42 Estimated 2 compartmental human iv PK parameters of FLU in PPI1501 in human assuming the same difference ratio of critical 2compartmental values observed in rats applies to human Estimated inEstimated in solution* PP11501 FA** Ka 1/h 58 V L 4.984 8.474 5.11 CLL/h 0.967 0.578 1.14 V2 L 2.199 1.341 3.28 CL2 L/h 0.343 0.061 4.40 MRTh 7.43 16.99 7.36 (est. based on 2 compartment model) *estimated basedon literature reported oral PK of FLU and estimated oral bioavailability(report for project 1) **values from project 1 report.

These compartmental parameter values were further used to simulate theIV time-concentration profiles of FLU in solution vs those in PPI 1501and IV dosed prodrug FA (FIGS. 23-25).

FIG. 23 depicts comparative simulation of human FLU concentrationfollowing a single iv dose of 100 mg FLU in solution (the upper line attime 0) vs PPI 1501 formulation (the upper line at 24 h) and FA (thelower line). Here, a 4 mg/L concentration represents the threshold painre-occurrence level.

FIG. 24 depicts comparative simulation of human FLU concentrationfollowing bid iv dose of 100 mg FLU in solution (the upper line at time0) vs PPI 1501 formulation (the upper line at 24 h) and FA (the lowerline). The horizontal line corresponds to 4 mg/L concentrationrepresents the threshold pain re-occurrence level.

FIG. 25 depicts Comparative simulation of human FLU concentrationfollowing q6 h iv dose of 50 mg FLU in solution (the upper line at time0) vs PPI 1501 formulation (the upper line at 24 h) and FA (the lowerline). The horizontal line corresponding to 4 mg/L concentrationrepresents the threshold pain re-occurrence level.

As shown in FIG. 23, the plasma concentration of FLU was greatestfollowing IV administration of 100 mg of the drug as a simple solution;the lowest peak plasma concentration was displayed when 100 mg of FLU inPPI 1501 was administered; in all cases however Cmax were greater thanthe putative minimum therapeutic FLU concentration of 4 mg/L. However,the PPI 1501 formulation delivered the highest plasma concentrationsafter 4 hrs and maintained the plasma concentrations>4 mg/L for over14.9 hrs. In comparison, following the same IV dose of FA, the durationof plasma concentrations>4 mg/L was only 5.5 hrs, almost 3-fold shorter(FIG. 23); The FA injection also resulted in the highest plasma Cmax/C24ratio, a parameter closely related to the safety profile of FLU (Table43). FLU from PPI-1501 exhibited the lowest such ratio.

Similar results were observed following bid iv dose of 100 mg, or 4times a day at 50 mg FLU in solution vs that in PPI 1501 formulation andIV dosed FA (FIGS. 24 and 25). In particular, the plasma FLUconcentrations remained >4 mg/L for 23.2 hrs and >24 hrs following theIV dose of FLU in PPI 1501 formulation only, compared to 12.5 hrs inboth dosages following IV doses of FA (Table 43).

TABLE 43 Comparative PK parameters of FLU in solution and in PPI 1501 vsthat of FA following different iv dosages Improvement AccumulativeAccum. Duration Duration Improvement C_(max) C24 C_(max)/C₂₄ (time > vs.FA C_(max)/C₂₄ Ratio Dosage Formulation (mg/l) (mg/l) (Fold) 4 mg/L, h)(fold) (fold) 100 mg qd FLU Solution 20.1 0.59 34.1 7.4 1.3 1.1 FLU PPI11.8 2.17 5.4 14.9 2.7 6.9 FA 13.6 0.36 37.8 5.5 1.0 1.0 100 mg bid FLUSolution 22.1 2.67 8.3 17 1.4 0.9 FLU PPI 16.7 7.07 2.4 24 1.9 3.1 FA15.3 2.07 7.4 12.5 1.0 1.0 50 mg q6h FLU Solution 14.2 4.5 3.2 21.5 1.71.0 FLU PPI 13.7 8.9 1.5 23.2 1.9 1.9 FA 9.9 3.3 3.0 12.5 1.0 1.0

In conclusion, the present study demonstrated that FLU in PPI 1501 inrats showed a higher AUC post delivery than that achieved by FLU insolution or FA, mostly due to the reduced drug clearance. Assuming thesame differences of 2 compartmental parameters apply similarly to human,then the 100 mg FLU qd dosing, or bid, or q6 h of 50 mg, may have anadvantage of achieving plasma concentrations>4 mg/L (a thresholdeffective concentration) for 14.9 and >23.2 hrs, ˜3 or 2 fold betterthan IV dosed FA. In addition, the reduced Cmax/C24 ratio may berepresenting another benefit for the safety profile.

Example 5: Protection from Haemolysis Introduction

The haemo-protective effect of API formulations comprising the PVP-PLAblock copolymers was studied.

Methods

The PVP-PLA block copolymers tested were from a further synthesizedbatch, in which n=27 (average value), m=35 (average value),Mn(PLA)=2075, Mn(PVP)=3980), and Mn(PLA-PVP)=6055 (as determined byNMR). The % PLA was 44%, and the % PVP was 56 (the latter two valuesdetermined by TGA). Accordingly, the polymer would be understood to bewithin the broadest parameters of Groups 1 to 3, as defined here.

To test the ability of the formulations to mitigate the haemolyticpotential of the API, in vitro haemolysis experiments were conducted asfollows. Human red blood cells (RBC) were isolated by centrifugationfrom whole blood collected in vaccutainer containing EDTA. RBC werewashed three times in normal saline and finally diluted in PBS 9:1 at pH7.4. Freeze-dried formulations were reconstituted in water and thendiluted to the desired concentrations with PBS. RBC suspension was mixedwith formulations to generate a final concentration of API from 0.05mg/mL to 5 mg/mL (it being understood that a 5 mg/mL concentration ofAPI in the blood of a human is far greater than that that could be usedtherapeutically), incubated at 37° C. for 60 min and centrifuged toremove intact RBC. 0.1 mL of supernatant was diluted with 0.75 mL of PBSand transferred to cuvette. Absorbance A of such solution was determinedat 540 nm using Agilent Cary UV-Vis-NIR 5000 spectrometer. Controlsamples for 0 and 100% haemolysis were prepared by incubating RBC withPBS and 1% Triton X-100, respectively, Percent haemolysis is expressedas 100×(A−A₀)/(A₁₀₀−A₀), where A₀ and A₁₀₀ is absorbance of negative andpositive control, respectively.

Results

FIG. 26 shows percent haemolysis measured for non-formulatedflurbiprofen and PVP-PLA/FLU formulation (DLL=20%) at the sameconcentration of 5 mg/mL. The data represent a single experimentconducted in triplicate±standard deviation. Measured absorbance valuesat 540 nm were as follows: 0.10±0.01 (0% haemolysis control), 0.58±0.03(100% haemolysis control), 0.12±0.01 (FLU/PVP-PLA), 0.54±0.03 (FLU).Non-formulated flurbiprofen (FLU) shows significant haemolytic activity,resulting in the high value of 92.1±17.2% of haemolysis. In contrast,when FLU is entrapped into PVP-PLA vehicles (FLU/PVP-PLA), essentiallyno haemolysis is observed (% haemolysis=3.1±0.6%), showing strongprotective effect of polymer micelles on the encapsulated drug.

FIG. 27 shows percent haemolysis for different concentrations of drug informulations of flurbiprofen (FLU), celecoxib (CEL), and acetaminophen(APAP). The data points represent single experiments conducted intriplicate±standard deviation. Essentially no haemolysis (%haemolysis<10%) was observed for celecoxib and acetaminophenformulations in the whole concentration range studied, i.e. forconcentrations≤25 mg/mL and 50 mg/mL, for CEL and APAP, respectively.

Discussion

In all cases, the PVP-PLA micelles displayed the ability to mitigate thehaemolytic activity of APIs towards to red blood cells, therebyestablishing a protective effect. API such as Flu, APAP and Cel can havebeen shown to induce haemolysis in human red blood cells at variousconcentrations and to various degrees. Micelles, such as PVP-PLAmicelles, by encapsulation of API have been demonstrated herein topossess a heamo-protective effect whereby they mitigate the haemolyticactivity of the API. This is borne out most markedly by the experimentsinvolving flurbiprofen. This haemo-protective ability provides animportant safety feature for delivery of API, e.g., via the parenteralroute where initial concentrations of API may be very high.

Example 6: General Discussion

Novel PVP-PLA block copolymers have been described herein, along withnovel production methods that demonstrate a surprising efficiency ofsynthesis.

These copolymers have been used to increase the water solubility drugmolecules many thousand fold to produce novel dry and liquidformulations suitable for administration.

Trends in copolymer properties have been observed, such that polymerscould be designed for, e.g. a particular API, or to achieve a moreflexible drug delivery platform.

These novel formulations have been lyophilized to optimize theirstability at both room temperature and elevated temperatures as couldoccur from time to time. The solid products so produced reconstituterapidly in aqueous solution to generate very high concentration, lowviscosity liquids.

These liquids, when injected into animals, generate very generate highblood concentrations of their drug entrapped drug. Thus, the nature ofthe novel PVP-PLA species renders insoluble drugs soluble in aqueoussolution, maintains them in an amorphous form in both liquid and solidforms, stabilizes them, and delivers them rapidly and in highconcentration to the blood post-intravenous injection.

Such properties are ideal for, e.g., postoperative pain products, whichgenerate analgesia rapidly and reliably. The PVP-PLA polymersadvantageously prolong residence time in the blood, and thereby maintainanalgesia for longer. Some polymers have been shown to maintaineffective levels of and API in the blood for at least 12 hours. This canmean fewer injections for a subject, and less pain recurrence(breakthrough pain).

Most importantly such products may provide the patient with effectiveand safe, convenient, low discomfort analgesics with the opportunity toreplace, or significantly reduce the need for, opioid analgesics withtheir many drawbacks. The copolymers may be used, e.g., for oral orparenteral administration.

The block copolymers described were synthesized using a novel processthat produced high purity products in yields unexpected for this type ofsystem. The characteristics of the copolymers so synthesized enable arange of insoluble drugs to be entrapped in high concentration andrendered amorphous to enable rapid release in vivo once administered.

In the preceding description, for purposes of explanation, numerousdetails are set forth in order to provide a thorough understanding ofthe embodiments. However, it will be apparent to one skilled in the artthat these specific details are not required. In other instances,well-known electrical structures and circuits are shown in block diagramform in order not to obscure the understanding. For example, specificdetails are not provided as to whether the embodiments described hereinare implemented as a software routine, hardware circuit, firmware, or acombination thereof.

The above-described embodiments are intended to be examples only.Alterations, modifications and variations can be effected to theparticular embodiments by those of skill in the art. The scope of theclaims should not be limited by the particular embodiments set forthherein, but should be construed in a manner consistent with thespecification as a whole.

REFERENCES

-   1. Kazunari Masutani, Yoshiharu Kimura, PLA Synthesis. From the    Monomer to the Polymer, chapter 1, The Royal Society of Chemistry,    2015, pages 1-36.-   2. Ann-Christine Albertsson, Indra K. Verma, Recent Development in    Ring Opening Polymerization of Lactones for Biomedical Applications,    Biomacromolecules, 2003, 4, pages 1466-1486.-   3. Irene Bartolozzi, Roberto Solaro, Etienne Schacht, Emo Chiellini,    Hydroxyl end-capped macromers of N-vinyl-2-pyrrolidinone as    precursors of amphiphilic block copolymers, European Polymer    Journal, 2007, 43, pages 4628-4638.-   4. Lionel Delaude, Morgan Hans, Somenath Chowdhury,    Microwave-Assisted Synthesis of the 1,3-Dimesitylimidazolinium    Chloride, Org. Synth., 2010, 87, pages 77-87.-   5. Lei Xiong, Hong Wei JiangAffiliated withSouth China University of    Technology, Di Zhen Wang, Synthesis, characterization and    degradation of    poly(dl-lactide)-block-polyvinylpyrrolidone-block-poly(dl-lactide)    copolymers, Journal of Polymer Research, 2009, 16, pages 191-197.-   6. K M Park, C K Kim. (1999) Preparation and evaluation of    flurbiprofen-loaded microemulsion for parenteral delivery. Intl J    Pharmaceutics, 181: 173-179.-   7. R D Knihinicki, R O Day, G G Graham, K M Williams. (1990)    Stereoselective disposition of ibuprofen and flurbiprofen in rats.    Chirality, 2: 134-140.-   8. Szpunar, G. J., Albert, K. S., Bole, G. G., Dreyfus, J. N.,    Lockwood, G. F. and Wagner, J. G. (1987), Pharmacokinetics of    flurbiprofen in man. I. Area/dose relationships. Biopharm. Drug    Dispos., 8: 273-283.-   9. Cefali, E. A., Poynor, W. J., Sica, D. and Cox, S. (1991),    Pharmacokinetic Comparison of Flurbiprofen in End-Stage Renal    Disease Subjects and Subjects with Normal Renal Function. Journal of    Clinical Pharma, 31: 808-814.-   10. Taburet, A. M., Singlas, E., Glass, R. C., Thomas, F. and    Leutenegger, E. (1995), Pharmacokinetic comparison of oral and local    action transcutaneous flurbiprofen in healthy volunteers. Journal of    Clinical Pharmacy and Therapeutics, 20: 101-107.-   11. Qayyum, A., Najmi, M. H. and Farooqi, Z-R. (2011) Determination    of Pharmacokinetics of Flurbiprofen in Pakistani Population Using    Modified HPLC Method. J. Chromatogr. Sci. 49: 108-113.-   12. Kaiser D G, Brooks C D, Lomen P L. (1986) Pharmacokinetics of    flurbiprofen. Am. J. Med. 80(3A):10-5.-   13. Kumpulainen E, Välitalo P, Kokki M, Lehtonen M, Hooker A, Ranta    V P, Kokki H. (2010) Plasma and cerebrospinal fluid pharmacokinetics    of flurbiprofen in children. Br J Clin Pharmacol. 70:557-66 5

What is claimed is:
 1. A dry pharmaceutical composition comprisingPVP-PLA block copolymers as defined in Formula I:

wherein: x is an initiator alcohol having a boiling point greater than145° C., n is, on average, from 20 and 40, and m is, on average, from 10and 40, wherein the block copolymers have a number average molecularweight (M_(n)) of at least 3000 Da, in molecular association with atleast one active pharmaceutical ingredient (API).
 2. The drypharmaceutical composition of claim 1, which is reconstitutable in wateror an aqueous solution to form a liquid comprising nanoparticles formedof the PVP-PLA block co-polymers and comprising the at least one API. 3.The dry pharmaceutical composition of claim 1, which is freeze dried orspray dried.
 4. The dry pharmaceutical composition of claim 1, which isamorphous.
 5. The dry pharmaceutical composition of claim 1, which isstable for at least six months at 40° C.
 6. The dry pharmaceuticalcomposition of claim 1, having a drug loading level (DLL) of at least 5%wt/wt of the at least one API.
 7. The dry pharmaceutical composition ofclaim 1, wherein the boiling point of the initiator alcohol is greater200° C.
 8. The dry pharmaceutical composition of claim 1, wherein theinitiator alcohol is selected from the group consisting of: 1-hexanol;1-heptanol; diethylene glycol monoethyl ether; diethylene glycol monomethyl ether; triethylene glycol mono methyl ether; tetraethylene glycolmono methyl ether; oligo-ethylene glycol mono methyl ethers of formulaII

wherein a≥5; oligo-ethylene glycol mono ethyl ethers of formula III

wherein b≥1; and mixtures thereof.
 9. The dry pharmaceutical compositionof claim 1, wherein x is diethylene glycol mono ethyl ether (DEGMEE).10. The dry pharmaceutical composition of claim 1, wherein: n is, onaverage, from 21.5 to 28, m is, on average, from 18 to 37, the PVP-PLAblock copolymers have a number average molecular weight of 4600 Da to6600 Da, the PVP-PLA block copolymers comprise a PLA block which has anumber average molecular weight of 1600 Da to 2900 Da, the PVP-PVP blockcopolymers comprise a PVP block which has a number average molecularweight of 1900 Da to 4200 Da, a ratio of the number average molecularweight of the PLA block to the number average molecular weight of thePVP block (PLA:PVP) of 0.3 to 1.4, a weight average molecular weight(M_(w)) of the PLA in the block copolymers is 35% to 60%, based on thetotal weight of the polymer, and a weight average molecular weight(M_(w)) of PVP in the block copolymers is 40% to 65%, based on the totalweight of the polymer, wherein the number average molecular weight is asmeasured by proton nuclear magnetic resonance (NMR) and the weightaverage molecular weight is as measured by thermogravimetric analysis(TGA).
 11. The dry pharmaceutical composition of claim 10, wherein: nis, on average, from 21.5 to 28, m is, on average, from 25 to 37, thePVP-PLA block copolymers have a number average molecular weight of 4800Da to 6600 Da, the number average molecular weight of the PLA block is1600 Da to 2900 Da, the number average molecular weight of the PVP blockis 2700 Da to 4200 Da, the ratio of the number average molecular weightof the PLA block to the number average molecular weight of the PVP block(PLA:PVP) of 0.3 to 1.0, and the weight average molecular weight (M_(w))of PVP in the block copolymers is 40% to 65%, based on the total weightof the polymer.
 12. The dry pharmaceutical composition of claim 11,wherein: n is, on average, from 24 to 28, m is, on average, from 25 to33, the PVP-PLA block copolymers have a number average molecular weightof 5400 Da to 6600 Da, the number average molecular weight of the PLAblock is 2200 Da to 2900 Da, the number average molecular weight of thePVP block is 2700 Da to 3700 Da, the ratio of the number averagemolecular weight of the PLA block to the number average molecular weightof the PVP block (PLA:PVP) of 0.5 to 1.0, the weight average molecularweight (M_(w)) of PLA in the block copolymers is 35% to 50%, based onthe total weight of the polymer, and the weight average molecular weight(M_(w)) of PVP in the block copolymers is 50% to 65%, based on the totalweight of the polymer.
 13. The dry pharmaceutical composition of claim1, wherein the PVP-PLA block copolymers have a polydispersity index(PDI) of ≤1.8, wherein the PDI is as measured by gel permeationchromatography with light scattering (GPC-LS).
 14. The drypharmaceutical composition of claim 1, wherein the at least one API ishydrophobic.
 15. The dry pharmaceutical composition of claim 1, whereinthe at least one API comprises an analgesic.
 16. The dry pharmaceuticalcomposition of claim 15, wherein the analgesic comprises a nonsteroidalanti-inflammatory drug (NSAID).
 17. The dry pharmaceutical compositionof claim 16, wherein the NSAID comprises flurbiprofen.
 18. The drypharmaceutical composition of claim 16, wherein the NSAID comprisescelecoxib.
 19. The dry pharmaceutical composition of claim 15, whereinthe analgesic comprises acetaminophen.
 20. The dry pharmaceuticalcomposition of claim 1, wherein the at least one API comprises ananesthetic.
 21. The dry pharmaceutical composition of claim 20, whereinthe anesthetic comprises propofol.
 22. The dry pharmaceuticalcomposition of claim 1, which is reconstitutable in water or aqueoussolution to form an essentially clear liquid comprising nanoparticlesformed of the PVP-PLA block copolymers and comprising the at least oneAPI.
 23. The dry pharmaceutical composition of claim 22, wherein theessentially clear liquid comprises at least 20 g/L of the API.
 24. Thedry pharmaceutical composition of claim 10, which comprises at least twodifferent APIs.
 25. The dry pharmaceutical composition of claim 24,wherein the at least two different APIs are selected from the groupconsisting of flurbiprofen, acetaminophen, propofol, and celecoxib. 26.The dry pharmaceutical composition of claim 11, which comprises at leastthree different APIs.
 27. The dry pharmaceutical composition of claim26, wherein the at least three different APIs are selected from thegroup consisting of flurbiprofen, celecoxib, acetaminophen, andpropofol.